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This chapter clarifies the motivation for designing an integrated 
patent-based framework to evaluate innovation strategies and specifies 
the research question my PhD thesis seeks to answer. It also presents the 
scope, the research objectives and the structure of the thesis.  
1.1 Premise 
Technological innovation is the key driver for technological 
progress and firms’ economic growth. Since firms pursue different 
innovation approaches, they achieve different innovation 
performances. Actually, a firm’s ability to develop technologies and 
products is strongly conditioned by its stock of knowledge, expertise and 
technology from prior R&D (Arts, 2012). The R&D conducted by 
companies is an investment activity whose output is the firm’s knowledge 
stock. This asset positively contributes to the firms’ future financial 
performance and, then, to its market value (Hall et al., 2005). The higher 
the level of innovativeness of the invention, the higher the expected 
technological and financial impact. As a matter of fact, some new 
technologies can be considered as an extension of previous innovations, 
whilst others are breakthrough, discontinuous or disruptive.  
Analysing technological innovation requires objective and 
standardized data, thus scholars often refer to patents (Griliches, 1990). 
Actually, patents are a direct outcome of the inventive process, and 
more specifically of those inventions that are expected to have a 
commercial impact; furthermore, they capture the proprietary and 
competitive dimension of technological change (Archibugi and Pianta, 
1996). Since obtaining patent protection is costly and time-consuming, 
only inventions that are expected to provide benefits that outweigh cost 
are applied. Patents have been treated as the most important output 
indicators of innovative activities and patent data have become the 
focus of many tools and techniques to measure innovation (Ma and Lee, 
2008). Among the information available in such documents, technology 
classification, assignee field, citations and patent families are used to 
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define different innovation metrics (Ahuja and Lampert, 2001; Graff, 
2003; Belderbos et al., 2010; Al-Ashaab et al., 2011; Geum et al., 2013).  
1.2 Problem description and research question  
The aim of this thesis is to define which strategical, technical and 
organizational issues affect innovative processes, their outputs and the 
quality of such innovation outputs. Actually, despite technological 
strategies implemented by innovative firms are widely investigated in 
literature, most attention has been devoted to only one dimension of 
R&D processes at time. Since innovation processes are featured by 
extreme complexity, I suggest a multidimensional approach, which 
provides a more complete overview of such processes, proposing a 
practical instrument useful for both business analysts and researchers, 
allowing them to detect, for instance, the determinants of high quality 
innovations. 
Hence, this work constitutes a contribution to the analysis of 
innovation strategies by posing the following research question: are 
patent data useful to provide a complete overview of innovation 
processes carried out by companies? 
1.3 Aim of the research  
The research presented in this thesis proposes an integrated 
framework for defining innovation strategies carried out by companies 
through the analysis of information disclosed in patent data. 
The proposed framework is based on the combination of five 
dimensions: 
• technological strategy carried out for each knowledge domain 
involved in the innovation process; 
• technological specialization within the technological field;  
• openness of the innovation process; 
• type of innovation resulting from R&D efforts; 




 Hence, the research objectives of my PhD thesis are the following: 
O1: Literature review  
To review the state-of-the-art of innovation research on each 
dimension under investigation, identifying the operationalisations mostly 
acknowledged by scientific literature.  
O2: Patent-based framework for innovation strategy  
To design a methodology that investigates each dimension and 
provides a more complete overview of innovation processes, also 
detecting the relationships among such dimensions. 
O3: Validation 
To test the methodology with an empirical study on top R&D 
spending companies belonging to bio-pharmaceutical and technology 
hardware & equipment industries, in order to validate both the 
framework applicability and its explicative power and usefulness. 
1.4 Structure of the thesis  
In the following section, I give a summary of the contents of my 
thesis, which is structured in five main parts:  
Part I: Literature review. This part discusses the literature 
contributions about technological strategies, technological 
specialisation, openness of innovation processes, type of innovation and 
quality of innovation output. As such, the section attempts to summarize 
the state-of-the-art of innovation research. 
Part II: Framework definition. In this part, the thesis will assume its 
experimental characteristic. Indeed, the patent-based framework for 
defining innovation strategies will be presented. Starting from the analysis 
of the operationalisations suggested by scientific literature, patent-
based metrics are defined to summarise each dimension under 
investigation.  
Part III: Framework application. This methodology will be validated 
through an empirical study on the sample under investigation. This part 
9 
 
will be also dedicated to the evaluation of the results, reporting the 
statistical analyses. In addition, some challenges in implementing the 
metrics proposed will be underlined.  
Part IV: Conclusions. This chapter includes the conclusions of the 
research: the major contributions, after both a theoretical and a 
practical perspective, will be provided. Limitations, future research lines 
and challenges will be also delineated. 
Part V: Supporting material. This section comprises the appendices 
A and B, useful to deepen methodology and results. They are attached 




2. LITERATURE REVIEW 
In this chapter, I aim at providing a theoretical overview on the 
issues addressed in the thesis, discussing literature contributions about 
knowledge management, innovation management and open 
innovation. Since the suggested framework consists of five dimension 
under investigation, I dedicated a specific literature review to each one.  
2.1 Technological strategy 
The technology of a firm is the result of its accumulated experience 
in design, production, problem-solving and trouble-shooting activities. 
Companies progressively accumulate their technological knowledge; 
therefore, firm’s existing stock of knowledge is history dependent and 
affects its future technological development (Tsang, 1997). 
Technological innovation is featured by searching activities of optimal 
alternatives addressed to identify and solve technical problems (Nelson 
and Winter, 1982). Through such activities, companies may improve their 
current technological capability or develop new capabilities. 
Technological innovations are based on the recombination and the 
integration of capabilities belonging to different knowledge domains, 
therefore such processes depend on the experience accumulated by 
the company. Actually, companies operate using a wide range of 
knowledge domains and differ in their technological diversity (Pavitt et 
al., 1989). Furthermore, in industries characterised by intense R&D 
activities, the competencies required to manufacture a product include 
multiple knowledge domains (Figure 1).  
Therefore, companies pursue different innovation approaches that 
lead to different innovation performances, depending on the specific 
technological strategy adopted to achieve a competitive advantage in 
the industry in which each firm is involved. This process is not static, with 
companies expanding their breadth of knowledge over time (Pavitt et 
al., 1989; Chang, 1996; Miller, 2004): knowledge does not have a rigid 
nature, but it can be transformed, accumulated, stored and transferred 





Figure 1. Stock of knowledge as the set of technological fields investigated by 
the company. 
The dynamic evolution of capabilities is influenced by the 
exploitation vs. exploration strategy adopted by a company. March 
(1991) made an explicit distinction between exploration and 
exploitation; the former refers to the creation of new capabilities by 
means of activities such as fundamental research, experimentation, and 
search. The latter concerns the leveraging of existing capabilities by 
means of activities such as standardization, upscaling, and refinement. 
Figure 2 shows the effects of exploitation and exploration strategies on 
the stock of knowledge. Among the knowledge fields owned by a firm, 
in year t 1,3,5 and 6 are exploited, while 2,4 and 7 are not involved in new 
inventions, but they will still be part of the stock of knowledge because 
of the experience accumulated by the company, unless they will be 
abandoned in the following years. The orange bubble represents a new 
technological domain that is explored by the firm in year t. Therefore, 





Figure 2. Effects of exploitation and exploration on the stock of knowledge. 
Specifically, exploitation strategies are associated with experiential 
refinement, selection, reuse of existing routines, upscaling, 
standardization and recombination and are aimed at strengthening 
basic knowledge already owned by a company, and increasing the 
degree of novelty with a limited risk, within the boundaries of the present 
concepts and architectures (Simon, 1991). Exploitative activities improve 
the effectiveness and the efficiency of existing capabilities, require the 
creation of economies of scale and lead to short-term effects (Belderbos 
et al., 2010). Exploitation, more often than not, generates incremental 
knowledge with moderate but certain and immediate returns (Schulz, 
2001). Therefore, exploitative strategies are based on the local search 
and build on the existing technological trajectory, aiming at improving 
existing product-market domains (He and Wong, 2004). On the other 
hand, the exploration of new possibilities and ideas is based on distant 
search and associated with experimentation, play, risk taking, in order to 
both create new capabilities (Belderbos et al., 2010) and produce new 
knowledge (Miner et al., 2001). Such novel body of knowledge will serve 
as the seed for future technological development (Miller et al., 2007) with 
companies involved in shifting to a different technological trajectory 
(Benner and Tushman, 2002) and aiming at entering new product-
market domains (He and Wong, 2004) in order to achieve a long-term 
growth. Moreover, to execute distant search, a firm must identify distant 
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knowledge domains from outside its boundaries and transfer them inside 
(Miller et al., 2007). For instance, firms’ members may attend 
conferences, browse patents, read trade journals or reverse-engineer 
competing products. Otherwise, companies may hire new skilled 
personnel in order to acquire their competencies in specific 
technological domains. In general, the capability to assimilate, assess 
and use new knowledge depends on firm’s absorptive capacity (Cohen 
and Levinthal, 1990). 
Even though exploration and exploitation compete for scarce 
organizational resources (March, 1991; 1996; 2006) and are self-
reinforcing, adopting only one strategy may lead to a trap. Exploitation 
leads to early success, but often creates a success trap, with existing core 
capabilities turning into core rigidities, reducing the ability of the firm to 
adequately respond to technological changes and compromising the 
long-term survival (Leonard-Barton, 1992; Christensen and Overdorf, 
2000). Differently, exploration often leads to failure and requires high 
commitment and investments, thus relying solely on it negatively affects 
firm’s financial performance (i.e. failure trap). Therefore, firms benefit 
from a balanced mix of exploration and exploitation strategies and the 
combination of both strategies improves survival chances, growth and 
financial performances (O’Reilly and Tushman, 2004).  
Table 1 summarizes the contribution provided by innovation 
literature about the definition of the different features regarding each 
technological strategy (Cohen and Levinthal, 1990; Simon, 1991; Miner 
et al., 2001; Schulz, 2001; Benner and Tushman, 2002; He and Wong, 2004; 
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Table 1. Exploitation vs. exploration strategy. 
Gupta et al. (2006) suggested that, within a single technological 
domain, exploration and exploitation are mutually exclusive, whilst 
across different areas they are orthogonal, thus high levels of exploration 
or exploitation in a specific domain may coexist with high levels of 
exploration or exploitation on other ones.  
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2.2 Technological specialization 
Although scientific literature takes into account the frequency with 
which companies operate within a specific technological field, no 
contribution was uncovered about the weight of such field on the overall 
innovation strategy carried out by firms. As a matter of fact, not all the 
domains are equally relevant for the company: only some knowledge 
areas are strongly stressed and mostly contribute to the development of 
the core technology of current business activities. Therefore, a different 
technological specialization may be detected in each technological 
field. Overall, companies concentrating their R&D efforts on few relevant 
fields are carrying out a focalization strategy. Conversely, working on a 
larger body of knowledge is related to differentiation strategies. 
In literature concerning innovation management, few contribution 
take into account the trade-off between specialization and 
differentiation, therefore the topic is under-researched. A similar concept 
is expressed by the so-called technological familiarity, i.e. a component 
is familiar to the firm when it has been recently and frequently used 
(Fleming, 2001; Arts and Veugelers, 2012).   
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2.3 Openness of the innovation process 
Regarding the organizational dimension of R&D, companies can 
carry out the entire innovative effort within their boundaries, pursuing a 
closed innovation (CI) strategy, or open up their R&D processes, 
adopting an open innovation (OI) approach. 
2.3.1 Closed vs. open innovation 
In a closed system, new products and services are developed in-
house and exploited by the company to enter the market first and win. 
After an open perspective, innovations are the result of collaboration 
efforts with third parties. By carrying on a CI strategy, capabilities and 
technologies are developed within the boundaries of the innovating firm 
and improved in order to reach the market and generate revenues. On 
the contrary, by implementing the OI strategy the boundaries of the 
innovation funnel become permeable (Chesbrough, 2003) with R&D 
projects a) jointly developed with other parties, b) developed by third 
parties before entering into the funnel or c) started by the company but 
leaving the funnel and further developed by third parties. The OI 
paradigm is conceived on the idea that companies are unable to hold 
in-house all the competencies they require, thus forcing them to open 
up their R&D processes. In the last decade, inter-firm R&D collaborations, 
strategic technologies alliances, joint development with universities and 
research groups, complex innovation networks and joint venturing 
investments have been incorporated into companies’ technological 
strategies, since they give access to different knowledge bases and new 
resources. 
Even though, in the last decade, inter-firm R&D alliances have 
become crucial for many companies belonging to industries featured by 
intense R&D activities, firms still prefer to develop internally their core 
products, without collaborating or outsourcing. Actually, they can be 
produced better, faster, and more efficiently internally and alone than 
in collaboration with other companies. Firms protect their invention with 
intellectual property rights and exploit the results of their R&D efforts in 
order to gain competitive advantage. Indeed, companies are rebuilding 
their internal R&D organization: already twenty years ago, Archibugi and 
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Pianta (1996) found that the importance of large in-house laboratories 
was declining and the international dimension of the innovation process 
was growing. The increasing geographic distribution of R&D activity is still 
an important phenomenon of globalization (Lahiri, 2010): firms 
decentralize their R&D activities and even more involve their subsidiaries 
in the technological development. 
Even though centralized R&D can generate technologies of 
greater impact (Argyres and Silverman, 2004), firms achieve exploitation 
through specialization, dividing themselves into various units to focus 
efforts on specific products and geographic markets (Miller et al, 2007). 
The higher the complementarity of assets needed to bring products to 
market, the greater the divisionalisation of a company. Firms may 
geographically distribute their R&D activities in order to share and 
allocate different technological domains (Nayyar and Kazanjian, 1993; 
Nerkar and Roberts, 2004). Further, divisionalisation might result from 
merger and acquisition activities: in order to avoid the loss of the 
capabilities of the new subsidiary, it is usually best to allow it to remain 
intact. 
In addition to their local inputs, firms may source knowledge from 
distant units (Venaik et. al., 2005). Such inputs comprise new knowledge 
both created in the distant unit and sourced externally by the distant 
unit. According to Lahiri (2010), with increasing geographic distribution 
of R&D activities, two issues may be defined: a) search costs increase, 
creating diseconomies of scale and b) transferring new knowledge from 
one unit to another becomes challenging. 
2.3.2 Equity vs. non-equity alliances 
Among the different OI practices, a distinction can be made 
between equity alliances and non-equity alliances. Within equity 
alliances (i.e. joint ventures) companies agree to share capital, 
technology, human resources, risks and rewards and establish a new 
entity under shared control. From a knowledge perspective, equity 
alliances provide the highest level of partner interaction and are 
considered as the most effective means of knowledge transfer (Anand 
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and Khanna, 2000). The joint creation of new knowledge requires high 
levels of resource commitment (e.g. capital, employees, time), equal 
motivation from both firms, and appropriate control mechanisms (Kogut, 
1988). Conversely, non-equity alliances (i.e. R&D collaborations) are 
characterized by lower resource commitment and give access to new 
knowledge bases, ideas and possibilities through the interaction with 
partners (Granovetter, 1973). Collaborations may differ in frequency and 
duration of the relationship and number of partners. Therefore, in an OI 
system companies establish a complex inter-firm network of relationships 
with other organizations, in which each one teams up to generate new 
products and technologies (Dittrich and Duysters, 2007). 
Many scholars studied the relationship between alliances and 
exploitative vs. explorative strategies. As to exploitation, intense 
collaborations with partners are required in order to achieve recurrent 
and trustful relationships (Krackhardt, 1992) and the creation of 
economies of scale. Companies pursuing an exploitation strategy will 
search for firms with similar technological capabilities: the collaboration 
needs time to build up and generates long-term benefits. Therefore, joint 
venturing strategies are mainly adopted in exploitative activities (Koza 
and Lewin, 1998), since companies need to establish strong ties with their 
partners and strong legal agreements. As of explorative strategies, they 
are pursued through alliances with partners with different capabilities, 
which give access to a different knowledge base. When exploring new 
technologies, firms need a more flexible form of alliance, since the result 
of the partnership is typified by more uncertainty and they need to have 
the possibility of abandoning the alliance at any given moment (Duysters 
and De Man, 2003). Furthermore, explorative activities require a 
continuous scanning of new technological opportunities. Since these 
opportunities often arise outside existing partners, partner turnover will be 
high (Dittrich and Duysters, 2007). For such reasons, non-equity alliances 
are strongly preferred in exploration strategies.  
Given that collaborative R&D activities are characterised by a 
larger field of application, the adoption of non-equity alliances is 
expected also in exploitation strategies. Actually, many scholars 
19 
 
discovered that companies jointly develop new products in order to 
share the costs of exploiting a certain form of technology (Nakamura et 
al., 1996) and share risks and costs of innovation under growing 
technological complexity (Hung and Tang, 2008). In addition, in industries 
featured by high market fragmentation companies with similar core 
business activities collaborate in standardization consortia, setting the 
standard for a particular technology (David and Steinmueller, 1995; 
Schmidt and Werle, 1998; Egyedi, 1999; Hawkins, 1999). 
2.3.3 R&D collaboration 
Companies can build their stock of knowledge not only through 
internal efforts, but also opening up their R&D processes. The OI 
paradigm (Chesbrough, 2003) is conceived on the idea that when the 
innovation funnel boundaries become permeable, firms are able to 
explore and exploit technologies by sharing their innovative processes 
with third parties. Therefore, OI describes a new opportunity for a firm’s 
strategy to profit from innovation, suggesting that companies should use 
inflows and outflows of knowledge to foster internal R&D, and to expand 
markets for external use of innovation, respectively (Chesbrough, 2006). 
OI has become one of the most addressed research topics in innovation 
studies, and many scholars investigated the impact of such strategy on 
companies’ stock of knowledge. In particular, when internalization 
strategies are pursued, external know-how can be acquired from third 
parties or shared within collaborative development processes (Schroll 
and Mild, 2011). Different business models can emerge from OI adoption, 
ranging from R&D collaborations to the incorporation of knowledge-
intensive firms (Michelino et al., 2015a). 
This work focuses on the collaborative dimension of OI, by 
investigating the impact of R&D collaboration activities on firms’ stock of 
knowledge and innovation performances. Actually, for firms operating in 
dynamic environments - featured by rapid development and increasing 
knowledge complexity - it is very difficult to contain and capitalize on all 
relevant knowledge. Therefore, companies specialize and employ R&D 
collaborations to complement their knowledge (Perez et al., 2013). This 
leads to the creation of complex networks of relationships with 
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customers, suppliers and other public and private organizations, in which 
companies team up to generate new products and technologies 
(Dittrich and Duysters, 2007). Indeed, firms may potentially learn from 
such interactions, which open up opportunities for joint value creation 
and innovation (Prahalad and Ramaswamy, 2004). Therefore, the joint 
development can be a source of competitive advantage, since it gives 
access to external sources and information (Belderbos et al., 2004). For 
these reasons, R&D collaborations and strategic technological alliances 
are increasingly part of companies’ innovation model (Archibugi and 
Pianta, 1996). However, many difficulties in managing the complexity of 
such relationships occur; therefore, the share of alliance failures is 
significant (Patzelt and Shepherd, 2008). Thus, a key determinant for a 
successful collaboration is the absorptive capacity, which is “the ability 
of a firm to recognize the value of new, external information, assimilate, 
and apply it to commercial ends” (Cohen and Levinthal, 1990). 
In summary, the reasons why companies enter into R&D 
collaboration are various: 
• it can help firms to reduce uncertainty in terms of costs and risks 
(Tyler and Steensma, 1995; Das and Teng, 2000), share the costs of 
exploiting a certain form of technology embodied into new 
products (Nakamura, 2003), share risks and costs of innovation 
under growing technological complexity (Hung and Tang, 2008); 
• it is required to shorten innovation cycles (Pisano, 1990) and enter 
the market first and win; 
• it is necessary to define regulations and industry standards more 
effectively (Benfratello and Sembenelli, 2002); 
• it gives access to new knowledge bases, ideas and possibilities 
through the interaction with partners (Granovetter, 1973); 
• it is source of complementary expertise for companies operating 
in industries typified by technological complexity, where no single 
firm possesses all the knowledge, skills and techniques required 




Many scholars studied the determinants of partners’ selection and 
defined different factors that affect the collaboration performance, 
such as: complementary skills and capabilities, cooperative culture, 
compatible goals, technological expertise, marketing system and 
knowledge, competitive strength, production efficiency, positive prior 
experience, labour negotiation experience, intangible assets, prior ties 
with universities (Brouthers et al., 1995; Rausser, 1999; Nielsen, 2003; Wu et 
al., 2009). 
2.3.4 Industrial vs. scientific partnerships 
Firms may collaborate with both industrial and scientific entities, 
such as other firms, universities and research centres. The most relevant 
advantages in collaborating with industrial partners are related to the 
access to complementary assets critical to successful development and 
commercialization, such as (Arora and Gambardella, 1990; Pisano, 1990; 
Teece, 1992): 
• market access; 
• marketing and distribution channels; 
• production facilities; 
• expertise in managing R&D and development processes; 
• financial capital to support the focal firm; 
• experience in evaluating payoffs far in the future; 
• experience on how to operate and grow a firm in the same 
industry; 
• strategic and operational know-how. 
Furthermore, such R&D alliances allow companies to: 
• possess stable exchange relationships (Stinchcombe, 1965); 
• acquire innovative capabilities (Shan et al., 1994); 
• achieve external endorsement of their operations (Baum and 
Oliver, 1991); 
• employ the perceived quality and reliability of their products and 
services among potential customers, suppliers, employees, 
collaborators and investors (Stuart, 1998). 
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On the other hand, firms provide their capabilities in new 
technologies and, then, their specialization, useful for their partners. For 
example, many biotech companies completely rely on OI as the unique 
source of revenues, by operating as innovation sellers with larger 
pharmaceutical firms (Michelino et al, 2015b). 
Regarding relationships with universities, research institutes, 
government labs and hospitals, various advantages in undertaking a 
collaboration can be defined: 
• the partners are a source of up-to-date information and 
knowledge, which is too tacit to be transferred through licensing 
or acquisition (Liebeskind et al., 1996);  
• collaboration with universities gives access to international 
knowledge networks (Okubo and Sjöberg, 2000) and, 
consequently, to international markets; 
• universities and scientific partners can be involved in developing 
prototypes and handling patents and licenses (Cyert and 
Goodman, 1997); 
• by collaborating with public entities, companies may access to 
public resources and funds (Bayona Saez et al., 2002). Therefore, 
the collaboration is stimulated by public programs which promote 
research and partnerships between public and private search; 
• R&D collaborations provide interaction opportunities, which 
generate new concepts, business ideas, emerging knowledge 
and technological know-how that firms can translate into new 
products (Powell et al., 1996); 
• R&D partners can give an answer to the demand for both basic 
knowledge and pre-competitive research (Arora and 
Gambardella, 1994) and more specific knowledge, focusing on 
problem solving and product design and development, i.e. 
applied research (Bayona Saez et al., 2002); 
• partnerships with universities and research centres allow 
companies to keep up-to-date in industrial standards and to 
access government information useful to find out what other firms 
in the sector are doing (Sakakibara, 1997). 
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R&D partnerships with universities and other scientific organizations 
are usually featured by long-term collaborations because of the basic 
and complex nature of the joint research, which requires larger learning 
processes (Hall et al., 2000a). In these partnerships, companies need to 
be particularly able to absorb the scientific knowledge transferred by 
partners and have a strong internal capacity for R&D (Bayona Saez et 
al., 2002). In many cases, the results obtained are not directly exploitable 
for business applications. Another relevant feature characterizing such 
collaboration is the geographical proximity, which significantly improves 
the efficiency of the alliances (Baptista and Mendonça, 2000). Actually, 
it simplifies and reduces the R&D efforts, which are affected by 
differences in aims, management styles and culture.   
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2.4 Type of innovation 
According to Henderson and Clark (1990), innovation can be 
defined from the analysis of two features: changes on core concepts 
and impact on the linkages between core concepts and components 
(Figure 3). 
 
Figure 3. Types of innovation (Henderson and Clark, 1990). 
The former refers to the novelty level of the innovation and has 
been widely explored in literature. Ahuja and Lampert (2001) termed 
technologies without technological antecedents as pioneering. Such 
technologies focus on completely de novo solutions. Actually, inventions 
without technological antecedents can be considered pioneering 
(Trajtenberg et al., 1992; 1997; Ahuja and Lampert, 2001; Rosenkopf and 
Nerkar, 2001; Shane, 2001; Kaplan and Vakili, 2012), while the existence 
of technological antecedents is a proxy of innovations based on the 
reinforcement of core concepts (Jaffe et al., 1993; Hall et al., 2001).  
Regarding the impact of the linkages between components, 
innovation can be achieved through recombining already established 
elements (Fleming, 2001) or by introducing an established element into 
a new setting (Hargadon and Sutton, 1997). Henderson and Clark (1990) 
argue that the mere rearrangement of previously used components can 
itself cause destabilizing industrial change. Therefore, new technologies 
can derive from the combination of elements and settings not previously 
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observed (Dahlin and Behrens, 2005). Thus, companies with most 
relevant skills and technology from prior related R&D can be capable of 
recombining these resources and capabilities in a novel way and 
originate innovation, i.e. recombining existing but disconnected 
technology components can foster innovation (Arts, 2012). The major 
technological shifts frequently emerge from the fertilization between 
different pre-existing but disconnected technology subfields or 
components (Basalla, 1988; Hargadon, 2003). By recombining different 
technology components, inventors search for those solutions with the 
highest fitness value (Fleming and Sorenson, 2001).  
From the matrix proposed by Henderson and Clark (1990) four types 
of innovation can be defined. When core concept are reinforced and 
linkages between core concepts and components are unchanged, the 
output of the R&D effort is an incremental innovation (Figure 4). 
Incremental innovations occurs also when only part of the components 
of an architecture are technologically improved, without changes in the 
architecture. Incremental innovation refines and extends an established 
design. Improvements occur in individual components, but the 
underlying core design concepts, and the links between them, remain 
the same (Henderson and Clark, 1990). These incremental technological 
improvements enhance and extend the underlying technology and thus 
reinforce an established technical order (Tushman and Anderson, 1986). 
 
Figure 4. Incremental innovation. 
On the other hand, when the components/modules are overturned 
and a new technology is employed within the architecture, a modular 
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innovation is obtained (Figure 5). The innovation relates to the 
introduction of new component technologies in specific parts of the 
product, without effects on the overall architecture. Thus, this implies that 
the innovation primarily affects isolated parts of the product system and 
that the technological novelty is concentrated to these parts. 
 
Figure 5. Modular Innovation. 
Regarding architectural innovation (Figure 6), it consists in the 
creation of new combinations of components (i.e. new settings), without 
using new technologies or core concepts; at most they are reinforced 
(even partially). Architectural knowledge concerns the ways in which the 
components are integrated and linked together into a coherent whole. 
Therefore, architectural innovation destroys the usefulness of a firm's 
architectural knowledge but preserves the usefulness of its knowledge 
about the product's components. The essence of an architectural 
innovation is the reconfiguration of an established system to link together 
existing components in a new way. This does not mean that the 
components themselves are untouched by architectural innovation. 
Architectural innovation is often triggered by improvements in a 
component (e.g. size or some other subsidiary parameter of its design) 
that creates new interactions and new linkages with other components 
in the established product. The important point is that the core design 
concept behind each component and the associated scientific and 




Figure 6. Architectural innovation. 
Finally, radical innovation is achieved when new technologies are 
combined with other components, in order to create a new 
combination, i.e. an architecture that strongly departs from past settings 
(Figure 7). Therefore, radical innovation is based on a different set of 
engineering and scientific principles and often opens up completely 
new markets and potential applications. Radical innovations establish 
new dominant designs and, hence, a new set of core design concepts 
embodied in components that are linked together in a new architecture 
(Henderson and Clark, 1990). They are fundamental changes that 
represent revolutionary change in technology and represent clear 
departures from existing practice. 
 
Figure 7. Radical innovation.  
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2.5 Quality of innovation output 
The quality of innovation output can be regarded as the impact of 
the new technology. At a very basic level, a distinction can made 
between inventions that impact from a technological perspective vs. 
inventions that are shocks from a user or market perspective (Ahuja and 
Lampert, 2001). 
From the technological point of view, inventions can be related to 
the concept of breakthrough innovation. Breakthroughs offer high 
improvements in the price vs. performance ratio over existing technology 
(Tushman and Anderson, 1986) and are generally considered as 
competence-destroying, since they are based on science and 
engineering principles rendering obsolete knowledge, capabilities and 
technology previously accumulated. Such inventions serve as the basis 
for many subsequent technological development (Trajtenberg, 1990a; 
1990b) and can be regarded as breakthrough because they have 
demonstrated their utility on the path of the technological progress 
(Fleming, 1998).  
Nevertheless, achieving such breakthroughs may not be wholly 
consistent with achieving economic impact, since a technology 
embodied in an invention requires several other factors, such as the 
reputation of the firm, the distribution of the idea in the network, the 
presence of complementary technologies (Kaplan and Vakili, 2012). 
Similarly, not all marketable innovations are necessarily technological 
breakthroughs: inventions that make an original idea more 
understandable and usable or that distribute it strategically in a network 





3. METHODOLOGICAL FRAMEWORK 
Starting from a literature review and focusing on the 
operationalization on patent data that are already acknowledged and 
adopted by scholars, I designed a patent-based framework with the aim 
of investigating the five dimensions of innovation previously defined and 
defining the relationship among them.  
Indeed, patent data are the only formally and publicly verified 
outputs of inventive activities and are widely accepted as a measure of 
innovation. As suggested by Griliches (1990), data provided by patents 
contain information about the whole population of innovating firms, are 
standardized, stored for a long period and continuously updated. Patent 
statistics provide very specific and detailed information for evaluating 
inventive activities (Acs and Audretsch, 1989; Chakrabarti, 1991; Grupp, 
1992). Furthermore, they are objective, since they have been processed 
and validated by patent examiners (Belderbos et al., 2010). In addition, 
they capture the proprietary and competitive dimension of 
technological change (Archibugi and Pianta, 1996). Since obtaining 
patent protection is costly and time-consuming, only inventions that are 
expected to provide benefits that outweigh cost are applied. For all 
these reasons, patents have been treated as the most important output 
indicators of innovative activities and patent data have become the 
focus of many tools and techniques to measure innovation (Ma and Lee, 
2008). Unlike other innovation metrics (e.g. R&D expenditures, number of 
R&D personnel) which regard the input of R&D activities, patent data 
focus on outputs of the inventive process, and more specifically of those 
inventions that are expected to have a commercial impact. They 
provide a valuable information about the effects of technological 
innovation and can be disaggregated to specific technological 
domains (Johnstone et al., 2012). For the analysis of specific 
development activities carried out by companies at the technological 
domain level, scholars refer to patent data for studying the relationship 
between innovation and knowledge (Almeida and Kogut, 1999; 
Abraham and Moitra, 2001; Ahuja and Katila, 2001; Ahuja and Lampert, 
2001). When they need to analyse knowledge domains, they focus on 
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International Patent Classification (IPC) codes, which identify the 
belonging technological fields of an innovation. Actually, all patents are 
categorised into at least one IPC: such technological index operates like 
a keyword system (Graff, 2003). IPC codes are widely employed to 
investigate technological innovation strategies implemented by 
innovative firms: e.g., Sakata et al. (2009) studied IPC combinations in 
order to define the innovation position of Japanese companies, while 
Suzuki and Kodama (2004) described technological trajectories and 
technological diversification strategies by examining patent 
classification codes. 
In this thesis, the analysis is performed at the knowledge domain 
level, evaluating the different innovation strategies adopted within each 
technological field involved in firms’ R&D efforts. Furthermore, the 
behaviours detected are taken into account in order to define the 
overall innovation strategy pursued by each company. In this thesis, I 
tested the framework on a sample of firms belonging to the bio-
pharmaceutical (BP) and technology hardware & equipment (THE) 
industries.   
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3.1 Priority patents and patent data 
The work examines the claimed priorities from the population of 
patent applications recorded in PATSTAT database, since these are 
considered the high-value applications (Harhoff et al., 2003; Johnstone 
et al., 2012). A priority filing is the first patent application filed to protect 
an invention. It is generally filed in the patent office of the inventor’s 
country of residence, although it may be applied elsewhere. Such filing 
is followed by a series of subsequent filings and together they form a 
patent family (Figure 8). Since such subsequent applications are the 
consequence of the first effort carried by a firm during the first filing, I refer 
only to claimed priorities. Furthermore, by considering only priority filings I 
can avoid to involve within the analysis multiple applications related to 
the same invention. Moreover, the priority date is the one closest to the 
period in which R&D activities were completed, thus supporting me to 
better define the reference year for the invention. 
 
Figure 8. Example of family size growth over time. 
Only patents filed at the EPO and USPTO offices were taken into 
account. I employed a broad set of patent information to model the 
respective variables: 
• Cooperative Patent Classification (CPC) codes; 
• list of companies disclosed in the assignee field; 
• backward and forward citations; 
• family size; 
• renewal fees. 
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In what follows, for each dimension under investigation I summarise 
the patent-based metrics mostly acknowledge by scholars and, starting 
from their operationalisations, I present how to implement the analysis 
within the following dimensions: 
• technological strategy; 
• technological specialization; 
• openness of the innovation process; 
• type of innovation; 
• quality of innovation output.  
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3.2 Technological strategy 
According to Belderbos et al. (2010), technological domains can 
be analysed in order to evaluate companies’ exploitation vs. exploration 
strategies: a patent is considered as explorative if it is situated in a 
technological domain in which firm lacks of prior familiarity. Therefore, 
explorative innovation activities develop ideas situated in knowledge 
fields where the firm has not patented in the past five years, whilst 
exploitative ones refer to technologies developed in knowledge areas 
where the firm has patented technology in the previous five years. This 
assumption is in line with the idea that knowledge evolves rapidly and 
companies lose most of their technical experience if they abandon a 
technological field for five years (Argote, 1999; Ahuja and Lampert, 2001; 
Fleming, 2001; Hall et al., 2005; Leten et al., 2007), with competencies 
previously accumulated resulting obsolete and forcing them to re-
explore such technological domain. Furthermore, when companies start 
to explore a new knowledge area, it remains relatively new until they 
accumulate experience in the search activity within it: such process 
requires time and resources; therefore, Belderbos et al. (2010) suggest 
that a technological field keeps its explorative status for a period of three 
consecutive years. 
Starting from this operationalization, I analysed classification codes 
disclosed in patent documents. For each analysed company I 
downloaded patent data from PATSTAT database, considering patents 
applied in the investigated time interval and detecting their classification 
codes. Even though scholars examine technological fields through IPCs, 
in this framework I refer to the Cooperative Patent Classification (CPC) 
system, a nomenclature developed by the European Patent Office 
(EPO) and the United States Patent and Trademark Office (USPTO) in 
order to allow inventors to retrieve relevant prior art efficiently. Actually, 
such system combines the best practices of the two offices and was built 
starting from IPC classification; therefore, it may be considered as its 
evolution, since it is more specific and detailed: while the IPC has about 
70,000 entries, the CPC has more than 250,000 ones, making it much 
more precise. The standardization allows to analyse patent applications 
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with both the EPO and the USPTO as a receiving office. Each CPC consists 
of a hierarchical symbol: the first letter defines the section, the two digits 
number denotes the class and the following letter identifies a sub-class. 
The sub-class is then followed by a one to three digits main group 
number, an oblique stroke and a number representing the sub-group. 
Unlike the operationalization applied in literature, I decided to cut the 
code and consider only the information before the stroke, since I believe 
that the operationalization of knowledge fields requires more 
generalization. For instance, Table 2 displays the hierarchical 
composition of the CPCs “H04W88/08” (i.e. access point devices) and 
“H04W88/12” (i.e. access point controller devices) with the interpretation 
about the meaning to be assigned for research purposes.  
Level Symbol Hierarchy Classification Meaning 
1 H Section Electricity 
Technological 
base 





































Table 2. Example of CPC hierarchical composition. 
By considering the entire code (level 5), I may study innovation at 
the component level, or rather at the maximum level of disaggregation. 
Since I aim at analysing innovative behaviours at the knowledge domain 
level, I require a higher level of aggregation and decide to consider the 
code at level 4 (i.e. until the main group). For example, both CPCs shown 
in Table 2 belong to the same technological field (i.e. devices specially 
adapted for wireless communication networks): I hypothesize that 
different products or components may be developed within the same 
knowledge domain since competencies required in the innovative 
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process are almost the same for both. Similarly, an excessive level of 
aggregation does not allow to correctly identify the various capabilities 
that a company owns. For each firm belonging to the sample, I detected 
from PATSTAT database the distinct CPCs disclosed in its patent 
applications. Each technological field is then labelled as exploitative or 
explorative. I started from the operationalization suggested by Belderbos 
et al. (2010):  
• a knowledge domain is labelled as exploitative if the company 
filed patents in such technological field in the past five years, 
explorative otherwise; 
• the technological field keeps its explorative status for a period of 
three consecutive years. 
The five-year time span is based on the assumption that companies 
lose their previous experience if they abandon a specific technological 
domain, while the three-year one, used for evaluating the exploration, is 
necessary for companies to master a knowledge field before it is 
exploitable. Yet, such hypotheses do not seem to take into account the 
different features of the belonging industry of companies. For instance, 
in the BP sector the development of a new drug can take more than five 
years: the lack of patent applications in a specific technological domain 
in the previous five years does not imply the loss of knowledge, since an 
invention may be in the development phase. Hence, the experience 
interval should consider the higher time-to-prototype and, thus, should 
be increased. On the other side, in the THE industry the faster 
development pace and the shorter product life cycles force companies 
to continuously adapt their technical competencies, which may be 
considered obsolete in a time span lower than five years. Thus, in order 
to take into account industry-specific time spans, I adjusted the 
experience interval: 
• by adding 2 years for companies belonging to the BP industry, 
resulting in a seven-year time span; 
• by removing 2 years for firms belonging to the THE one, 
considering a three-year time span. 
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Consequently, also the exploration interval is influenced by industry-
specific characteristics (e.g. product complexity and development 
pace), with BP companies requiring more time to make a technological 
field exploitable and THE ones forced to speed up the process of 
familiarization with a new knowledge domain. Therefore, the exploration 
time span is set at: 
• 4 years for companies in the BP industry; 
• 2 years for THE firms. 
Such operationalization is in line with the different market, product 
and industrial structures in which companies compete (Table 3). Without 
accounting for the time span adjustment factors, a comparison 
between the two industries may lead to inaccurate results. For this 
reason, I adjusted the values recognised in the scientific literature, which 




BP industry THE industry 
Product 
development time 
About 10-12 years1  About 1-3 years 
Research activity Basic research 





Industry standards and 
customer expectations 
Product Integral nature 
Modularity of IT design, 
component-based 
products 






Product covered by 
a small number of 
patents 
Many patents to assemble 
intellectual property rights 
for a single product 
Patenting strategy 
The company is the 
sole holder of a drug 
patent 
The firm holds just a large 
enough percentage of the 
total relevant patents 
Table 3. Market, product and industrial structure for BP and THE companies. 
                                                
1 Since bio-pharmaceutical companies have to apply the patent before a drug is 
subject to the evaluation of public health authorities, I assume that the invention is filed 




In order to label as exploitative or explorative each distinct CPC 
detected for every company, an examination of previous patent 
applications is required. Such study is limited by the experience interval 
defined for the belonging industry of the company. This range of time 
can be divided into two periods: the exploitation phase and the 
exploration one. Since the latter is previously defined and industry-
specific, the former is fixed by difference. For instance, in the BP industry 
I analysed only patent applications from t-7 to t-1, having considered a 
seven-year time span for the of experience interval: the period of 
exploration is 4 years, then the time span for the exploitation is 3. I am 
supposing that the knowledge owned by the company before t-7 is no 
more useful and available in t, if afterwards it was not further 
accumulated and recombined, bringing to a new patent application. 
Since a CPC is labelled as exploitative if the company has already 
patented within the knowledge domain and has already trespassed the 
exploration phase, in the BP industry only technological fields for which 
at least a patent application is detected from t-7 to t-4 can be 
considered as exploitative in t. However, if no patent was applied in such 
time interval, the technological field is still in the exploration phase: even 
though a patent application is detected from t-3 to t-1, I assume that in 
t within the knowledge domain the exploration phase is not yet complete 
(Figure 9). Therefore, if no patent application reporting the specific CPC 
was found from t-7 to t-1, the CPC is new for the company, since the first 
patent has been applied in t and the knowledge domain is labelled as 
explorative.  
 
Figure 9. Labelling of knowledge domains from patents filed by BP companies. 
As to the THE industry, I considered only patents from t-3 to t-1, and 
the CPC is labelled as exploitative if I find applications in t-3, explorative 




Figure 10. Labelling of knowledge domains from patents filed by THE companies. 
Hence, I investigated the features of each knowledge domain 
involved in each invention and I summarize such features through shares 
defining two variables: 
• EXPLOIT, as the ratio of CPCs in the exploitation phase declared 
within the patent application; 
• EXPLOR, as the share of CPCs in exploration phase recorded in the 
document.  
For instance, for a patent declaring four CPCs, of which three are 




3.3 Technological specialization 
After having labelled a CPC as exploitative or explorative, a 
second label is assigned: core vs. non-core. Since not all the domains are 
equally relevant for the company, only some knowledge areas are 
strongly stressed and mostly contribute to the development of the core 
technology of current business activities. I aim at distinguishing between 
inventions in core technological fields and those in non-core ones and 
evaluating if the different relevance significantly affects the choice of 
management and organization of innovation strategies. Also 
technological specialization is analysed using the 4-string CPC code. In 
particular, each CPC is defined as core if it is declared in at least 10% of 
the patents filed in the experience interval, non-core otherwise2. For 
instance, in the BP industry the relevance is estimated dividing the 
number of patents declaring the analysed CPC from t-7 to t-1 by the total 
amount of patent applications recorded from t-7 to t-1, considering only 
those reporting at least one CPC. This idea is based on the assumption 
that a technological field is core if its accumulation of knowledge in the 
experience interval generates a large number of patent applications. As 
in the case of technological strategy, a ratio of core and non-core 
technological fields is defined for each patent, named respectively 
CORE and NONCORE. 
In literature, a similar concept is expressed by the so-called 
technological familiarity. A component is familiar to the firm when it has 
been recently and frequently used (Fleming, 2001; Arts and Veugelers, 
2012). For each separate technological field disclosed in a patent 
document, scholars estimated an individual measure of component 
familiarity and the average component familiarity of the patent. 
Therefore, I deduce that familiarity can be seen as the absolute value 
from which I may derive a relative measure (i.e. technology 
specialization).  
                                                
2
 The threshold of 10% is based on robustness tests. Indeed, by setting up the 
threshold to 15% for many companies no core knowledge domains were found, whilst 
reducing it to 5% the majority of technological fields is labelled as core, impeding a good 
distinction between core and non-core CPCs. 
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3.4 Openness of the innovation process 
Regarding the management and organization of innovative 
activities, researchers focus on the assignee field disclosed in patent 
documents to define the openness of the process. When a firm develops 
in-house a new technology, only one applicant is recorded in the patent 
application. On the contrary, a co-assignment is detected when two or 
more companies are involved in the development and contribute to the 
final invention, sharing the ownership of the innovation. Thus, co-patents 
seem to be a relevant indicator for signalling the occurrence of OI 
strategies (Chesbrough, 2006) and the number of patents deriving from 
collaborative projects can be considered as a proxy of OI (Al-Ashaab et 
al., 2011). Kim and Song (2007), using joint-patenting information, 
reported a growing OI adoption. 
In order to delineate how companies manage and organize their 
R&D efforts, I refer to the assignee field disclosed in patent documents. 
Through the analysis of such a field, I am able to define which are the 
actors involved in the development of the invention.  
The first step of the analysis regards the linkage between the 
companies of the sample and the PATSTAT applicant table. For each firm 
I searched in the assignee field both the name of the parent company 
and its subsidiaries, disclosed in the 2011 annual report, also taking into 
account the names of the units previously acquired or merged.  
The second step of the analysis refers to the study of the companies 
disclosed in the applicant field. Since I left out any inventor from the 
framework, only firms are considered. I focus on the number of assignees 
recorded in patent documents in order to find information about the 
management and organization of the specific invention. Particularly: 
• if only one company is found, the patent is internally developed; 
• if two or more different organizations were found in the applicant 
field, I detect a joint patent among the analysed firm and third 
parties. 
Regarding the partner typology, each partner is labelled as: 
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• industrial company, if the patent document records a private 
organization; 
• scientific organization, when relationships involve universities, 
research institutes, government labs, hospitals and any other 
public authority. 
The purpose is to understand if the different partner typology 
features specific firms and affects other characteristics under 
investigation. Therefore, three indicators can be defined for each 
patent: 
• CLOSED, assuming value 1 if the patent has been internally 
developed, 0 otherwise;  
• OPEN_SCI, a dummy variable signaling the occurrence of 
scientific organizations on within the focal patent; 
• OPEN_IND, equals to 1 if at least an industrial partner has been 
detected for the focal patent.  
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3.5 Type of innovation 
Consistently with Henderson and Clark (1990), two features are 
investigated in order to identify the type of innovation: the novelty level 
of an innovation and the impact on the linkages between components. 
The former can be investigated through the analysis of backward 
citations. Actually, patents without backward citations to prior technical 
art can be considered pioneering (Trajtenberg et al., 1992; 1997; 
Rosenkopf and Nerkar, 2001; Shane, 2001; Kaplan and Vakili, 2012), while 
the existence of backward citations is a proxy of innovations based on 
the reinforcement of core concepts (Jaffe et al., 1993; Hall et al., 2001). 
Therefore, the lack of prior art citations is a proxy of originality, creativity 
and novelty of a patent. On the contrary, patents disclosing backward 
citations can be considered as spillovers. Even though the applicant may 
deliberately avoid backward citations, he has the legal duty to disclose 
any citation to prior art. The decision regarding which patents to cite 
ultimately rests with the patent examiner, who is an expert in the area 
and able to identify relevant prior art that the applicants omitted. 
Furthermore, applicants may cite their previous inventions, signalling an 
internal spillover and the reinforcement of their own core concepts.  
A significant contribution regarding such operationalization derives 
from Jaffe et al. (2000): conducting a survey on the determinants of 
citation selection, they discovered that the nature of the technological 
relationship between two patent could be different. For instance, the 
citing patent can be seen as an alternative way of doing something that 
the cited patent did before (i.e. similarity of application); otherwise, it 
could be that the citing patent does something different than the cited 
patent, but utilizes a similar method, even though the purpose is different 
(similarity of technology). 
Regarding the impact of the linkages between components, 
innovation can be achieved through recombining already established 
elements (Fleming, 2001) or by introducing an established element into 
a new setting (Hargadon and Sutton, 1997). Fleming (2001) suggested to 
proxy components with patent technological classes. Multiple 
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classification codes are usually assigned to a patent and they can be 
used to observe indirectly the process of recombinant search and 
learning. Such classification codes correspond to well-understood 
“hardware components” or “building blocks”, therefore I derive that their 
combination can be seen as an architecture.  
In summary, backward citations can be considered as a proxy of 
originality, creativity and novelty of an invention. Moreover, the CPC at 
level 5 (i.e. the entire code) was used to operationalize the components 
so that their combination constitutes an architecture. In order to 
understand whether the combination is “new to the world”, I verified if 
the same combination occurs in the experience period in all the patent 
applications recorded in PATSTAT database. Only when no identical 
combination was detected, the focal combination is regarded as new, 
i.e. the architecture is new. 
Therefore, in order to define the type of innovation, the following 
operationalization was adopted (Figure 11): 
• the novelty level of an innovation is analysed through backward 
citations; 
• the impact on the linkages between components is evaluated 
considering the novelty of the combination of technological fields 
disclosed in patent documents. 
For instance, I define as radical an innovation featured by 
technological originality and generating a new combination of 
technology components. Being measured ex-ante, the metric does not 
take into account the effective market and technological impact of the 




Figure 11. Types of innovation (adapted from Henderson and Clark, 1990). 
Therefore, 4 dummy variables can be defined: 
• INCR, equal to 1 for incremental innovations; 
• MOD, with value 1 if modular innovation has been detected; 
• ARCH, assuming 1 if the innovation is architectural; 
• RAD, equal to 1 if the innovation is radical.  
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3.6 Quality of innovation output 
The quality of innovation output can be regarded as the impact of 
the new technology. At a very basic level, a distinction can be made 
between inventions that impact from a technological perspective (i.e. 
breakthrough innovation) vs. inventions that are shocks from a user or 
market perspective (Ahuja and Lampert, 2001). 
Regarding breakthrough inventions, they can be identified through 
patent citation counts. When a patent is cited by other inventors, a 
higher technical importance can be presumed: patents that are cited 
are more relevant, innovative and important than those patents that are 
disregarded (Albert et al., 1991; Rosenkopf and Nerkar, 2001; Dahlin and 
Behrens, 2005; Alcácer and Gittelman, 2006; Miller et al., 2007; Lahiri, 
2010; Mazzucato and Tancioni, 2012). Fleming and Sorenson (2004) 
argued that the number of forward citations of a patent highly correlates 
with its technological importance, as measured by expert opinions, 
social value, and industry awards. 
From their survey, Jaffe et al. (2000) argued that a patent is cited 
when its technology is incorporated in other products or new markets are 
discovered for the same technology. Furthermore, highly cited patents 
usually lead to higher economic profits than patents that are less 
frequently cited (Harhoff et al., 1999; Hall et al., 2005). While the number 
of backward citations is a backward looking measure, which captures 
the relationship between a patent and the body of knowledge that 
preceded it, the number of forward citations is a forward-looking 
measure, which captures the relationship between a patent and 
subsequent technological developments that build up on it (Mazzucato 
and Tancioni, 2012). 
 In this work, I employed information provided by five-year forward 
citations (Hall et al., 2000; Lahiri, 2010), estimated as the number of 
patent applications declaring the focal patent in the five years following 
its publication. Such measure can be regarded as a proxy of the 
technological value of the invention (Miller et al., 2007). 
46 
 
Yet, not only technological quality has to be considered, since also 
patents with a low technological impact can have a market impact. 
Hence, I took into account the patent family size, estimated as the 
number of all patent applications - priority and non-priority - declaring 
the focal patent in the five years following its application. 
Actually, scholars measure technology marketability by 
investigating the patent family size. The Organisation for Economic Co-
operation and Development (OECD) defines patent families as “the set 
of patents filed in several countries which are related to each other by 
one or several priority filings”. Given the territorial character of patent 
protection, when an applicant wants to protect an invention 
internationally, a patent application has to be filed in each of the 
countries where protection is sought (either one by one or collectively 
through supranational filing procedures). As a result, the first patent filing 
made to protect the invention, the so-called priority filing, which is usually 
made in the home country of the applicant, is followed by a series of 
subsequent filings and forms, together with them, a patent family. The 
number of family patents represents the number of different nations in 
which a patent is published (Breitzman and Mogee, 2002; Harhoff et al., 
2003) and has been considered as indicating the level of R&D or 
technological activity relevant to international diffusion, thus implying 
marketability (Geum et al., 2013). Ernst (2003) used the average number 
of family patents granted by the organization in the technology areas of 
interest compared to the industry mean for evaluating the firm’s 
products marketability. The family size increases when inventions have 
been applied for protection in multiple countries (Johnstone et al., 2012), 
claiming the priority patent. Moreover, follow-on patents, also called 
continuations, may be further filed by applicants for numerous reasons: 
to apply for different uses from the same claims, and to file new claims 
that emerge over time in the R&D process (Gittelman, 2008). Graham 
and Mowery (2004) reported that about one quarter of patent 
applications are continuations on prior inventions. They are particularly 
important in fields where development processes are long, specifically 
bio-pharmaceuticals. In fields where life cycles are short (e.g., 
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semiconductors) they are more likely to be used for strategic purposes 
(Graham and Mowery, 2004). Even though many scholars discovered 
that patents in large families will be more likely to receive higher numbers 
of future citations (Cockburn and Henderson, 1998; Gittleman and 
Kogut, 2003; Harhoff et al., 2003), and then technological and market 
impact are closely related, as mentioned before not all marketable 
innovations are necessary technological breakthroughs. 
Finally, considering that it is expensive for owners to renew patent 
protection for additional years, I labelled as lapsed a patent whose fees 
result as unpaid within the eighth year, active otherwise. This can be 
viewed as a proxy of the value attributed to the invention (Pakes and 
Simpson, 1989). 
Actually, the quality of innovation output and, then, its impact, is 
defined through ex-post information provided by eight-year renewal 
fees, five-year forward citations and family size. Specifically, four levels of 
quality have been introduced (Figure 12): 
• low, for all lapsed patents and for active ones when neither 
forward citations nor patent extension were found; 
• technological, when only forward citations were detected; 
• market, if only an increase of the family size was discovered; 
• high, if both forward citations and patent extensions were 
uncovered. 
 
Figure 12. Quality of innovation output. 
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Therefore, I considered 4 dummy variables (MARK, HIGH, TECH, 
LOW) capturing the quality of innovation output for each patent 
application. For instance, when the market quality has been detected, 




3.7 The integrated patent-based framework 
The thesis investigates innovation strategies carried out by top R&D 
spending bio-pharmaceutical and technology hardware & equipment 
companies ranked by The 2011 EU Industrial R&D Investment Scoreboard. 
I selected these industries since they are the first for R&D investments and 
use patents as a means of appropriation of innovation (Pavitt, 1984). I 
employed information disclosed in patent documents and examined 
five dimensions of innovation. 
The selection of such dimensions has followed an input-process-
output-outcome logic. Actually, technological strategy and 
technological specialization affect the input of the innovative efforts, 
defining which expertise, capabilities and resources are involved in the 
R&D process. The “process” block can be summarized by the 
organizational dimension, which opposes closed, internal development 
to open, joint development. The type of innovation describes the 
innovation output, whose quality represents its outcome. Figure 13 
displays the innovation dimensions and their variables, also exhibiting the 
specific patent data employed for the operationalization of each block. 
The analysis is performed for each patent document; hence, I 
investigated the five dimensions of innovation within the focal invention. 
 
 
Figure 13. The input-process-output-outcome logic for defining innovation 
dimensions. 
The individual information collected for each patent is used to study 
the overall behaviour of a firm, cumulating the results obtained from all 








































• CORE is the share of patenting activities within CPCs labelled as 
core compared to the total amount of patenting activities in 
which the firm is involved in t; 
• EXPLOR is the share of explorative activities (i.e. activities within 
CPCs labelled as explorative) compared to the total amount of 
patent applications in t. 
Regarding metrics defined through dummy variables, I divided their 
occurrence by the total number of patent filed by the focal firm, e.g. 
RAD is the share of patents labelled as radical on the total number of 
patent applications owned by the company.  
The framework supports in identifying firms’ innovation strategies in 
a specific time interval and provides a useful instrument for 
benchmarking (i.e. firm-level analysis). Further, by selecting a sample of 
companies and cumulating the results obtained for each one, the 
framework also provides information about technological innovation in 
specific industries, enabling to perform an industry-level analysis. 
In Appendix A, I explain the methodology in detail, describing the 
process of data collection and the programming code developed in 
order to query the PATSTAT database. I also provide an example of the 
framework application to patent documents filed by Zeltia, a 
pharmaceutical firm, from 2003 to 2015. Limitations pertaining to both the 





4. FRAMEWORK APPLICATION 
The devised framework was applied to a sample of 223 R&D intense 
companies from BP and THE industries (Appendix B), ranked by their 
investment in R&D, according to The 2011 EU Industrial R&D Investment 
Scoreboard (JRC, 2011), in order to perform an industry-level analysis. 
Firms whose 2011 annual reports were not available on the internet and 
those for which the list of subsidiaries was not found in such documents 
were excluded. In detail, the sample consists of 78 BP companies and 
145 THE ones. I downloaded from PATSTAT database about 3,000 priority 
patents filed from 2003 to 2005 by BP companies and more than 20,000 
ones applied in the same period from THE ones, performing an industry-
level analysis for each sector. Then, I compared the results in order to 
detect differences in the adoption of innovation strategies between the 
two industries. Since a study of innovative activities within the experience 
period is required in order to label knowledge domains and detect 
technological and specialization strategies, I downloaded about 16,000 
patents filed by BP companies before 2003 and about 56,000 applied by 
THE ones. Each industry-level analysis is performed cumulating the results 
obtained for each company within the belonging sector.  
The data were used from a cross-section perspective, as three years 
are insufficient for a longitudinal study, especially in an industry like the 
bio-pharmaceutical where the development time horizon can be longer 
than ten years. Thus, ANOVA, descriptive statistics and correlation 
analyses were presented on a set of about 23,000 patent applications 
and 223 firms.  
Since very different business models feature the two industries under 
investigation, cross-section one-way ANOVA analysis was performed to 
determine whether the belongingness to the two industries is a 
discriminating factor for the variables under study (Table 4). All of them, 
except for the technological quality (TECH) resulted in statistically 
different mean values between the two industries and, for this reason, 
both descriptive statistics and correlation analyses were performed and 











Between 13.196 1 13.196 
92.323 0.000 Within  3,334.850 23,331 0.143 
Total 3,348.046 23,332  
NONCORE 
Between  13.188 1 13.188 
92.266 0.000 Within  3,334.883 23,331 0.143 
Total 3,348.072 23,332  
EXPLOIT 
Between  0.920 1 0.920 
6.064 0.014 Within  3,540.668 23,331 0.152 
Total 35,41.588 23,332  
EXPLOR 
Between  0.916 1 0.916 
6.033 0.014 Within  3,540.815 23,331 0.152 
Total 3,541.731 23,332  
CLOSED 
Between  1.182 1 1.182 
81.445 0.000 Within  338.716 23,331 0.015 
Total 339.899 23,332  
OPEN_SCI 
Between  0.400 1 0.400 
145.554 0.000 Within  64.194 23,331 0.003 
Total 64.594 23,332  
OPEN_IND 
Between  0.207 1 0.207 
17.536 0.000 Within  274.888 23,331 0.012 
Total 275.095 23,332  
INCR 
Between  49.473 1 49.473 
203.930 0.000 Within  5,659.991 23,331 0.243 
Total 5,709.464 23,332  
MOD 
Between  52.919 1 52.919 
901.334 0.000 Within  1,369.802 23,331 0.059 
Total 1,422.721 23,332  
ARCH 
Between  17.392 1 17.392 
70.584 0.000 Within  5,748.732 23,331 0.246 
Total 5,766.124 23,332  
RAD 
Between  15.441 1 15.441 
271.675 0.000 Within  1,326.042 23,331 0.057 
Total 1,341.483 23,332  
LOW 
Between  59.500 1 59.500 
939.165 0.000 Within  1,478.112 23,331 0.063 
Total 1,537.612 23,332  
TECH 
Between  0.00 1 0.000 
0.022 0.882 Within  214.982 23,331 0.009 
Total 214.982 23,332  
MARK 
Between  30.498 1 30.498 
364.920 0.000 Within  1,949.889 23,331 0.084 
Total 1,980.387 23,332  
HIGH 
 
Between  175.572 1 175.572 
1,289.748 0.000 Within  3,176.022 23,331 0.136 
Total 3,351.594 23,332  
Table 4. One-Way ANOVA - Discriminating Factor: Industry Belongingness. 
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4.1 Industry segments 
Within each industry, I also defined specific segments, on the basis 
of the 4-digit ICB codes disclosed in the Scoreboard, in order to detect 
behaviours depending on the peculiarities of business activities carried 
out by firms. For the BP industry two segments are defined: 
• pharmaceutical companies (PH), relying on a chemical-based 
synthetic process to develop small-molecule drugs. They generally 
have greater flexibility to either carry out those functions entirely 
in-house or license drugs from other entities, including biotech 
firms, for additional development. Furthermore, PH companies 
usually generate sales from products they already have on the 
market. Even though R&D costs are considerable, sales and 
marketing expenses are particularly relevant for them, since they 
are necessary to achieve their sales targets and maximizing 
profitable returns; 
• biotech companies (BIO), which use biotechnology to 
manufacture drugs, involving the manipulation of microorganisms 
or biological substances to perform a specific process. Focusing 
primarily on R&D, they discover novel compounds with processes 
often lengthy, difficult, and costly. Frequently, they operate at a 
loss for an extended period, and their R&D costs are typically 
driven by milestone payments related to collaborations with 
larger, more established biotech or PH companies. If a compound 
successfully progresses through the final stage of testing, a BIO firm 
may prepare for commercial launch or can partner up with 
another company in exchange for a portion of sales. 
Regarding the THE industry, three segments can be considered: 
• computer hardware & office equipment (CHOE), featured by 
businesses involved in designing and manufacturing computer 
hardware and components, such as monitors, data storage, hard 
drive disks, printers, photocopiers and computer networking 
infrastructures. The competition among CHOE companies is 
particularly intense. In the traditional PC market, companies' 
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products have largely become commodified, with constant 
downward price pressure (and narrowing profit margins) being 
the result. On the other hand, there are markets for innovative 
new products, like tablet PCs and ultra-minimal desktops, which 
are not yet fully commodified. Thus, the race is on to develop 
products at breakneck speed so they can be first to market. And 
if a company falters, it instantly becomes a target for larger 
companies looking to acquire new businesses; 
• semiconductors (SE), represented by companies engaged in 
design and fabrication of semiconductor devices, such as digital 
and analog integrated circuits. Firms within such segment are 
technology enablers for the whole electronics value chain. The 
segment is featured by the need for high degrees of flexibility and 
innovation in order to constantly adjust to the rapid pace of 
change in the market. Many products embedding 
semiconductor devices often have a very short life cycle. At the 
same time, the rate of constant price-performance improvement 
in the semiconductor industry is shocking. Consequently, changes 
in the semiconductor market not only occur extremely rapidly but 
also anticipate changes in industries evolving at a slower pace; 
• telecommunication equipment (TCE), concerning businesses 
involved in designing and manufacturing hardware used for 
telecommunications. Actually three main categories of products 
can be defined: public switching equipments (i.e. analogue and 
digital switches), transmission equipments (e.g. transmission lines, 
communications satellites) and private equipments, such as 
mobile phones, modems and routers. Profitability for individual 
companies is linked to technical innovation and the ability to 
secure high-volume contracts from large customers. Small 
companies can be successful if they make highly specialized 
products. There are large economies of scale in manufacturing 
standard products, but many products are specialized and 
produced in small manufacturing plants. 
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In what follows, descriptive statistics for the five dimensions under 
investigation are presented, performing both industry- and segment- 
level analyses. Finally, for each belonging industry I show the results from 
the correlation analysis with the aim to give evidence of the relationships 
among the five dimensions of innovation.  
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4.2 Technological strategy 
Table 5 displays the technological strategies carried out by the 
sample within the knowledge fields involved in R&D activities. By 
grouping firms by industry, no significant differences emerge: exploitation 
strategies are strongly preferred, covering about 70% of innovative 
activities. Even though companies need to combine both exploitative 
and explorative activities in order to effectively improve their survival 
chances and performance, the heritage of routines adopted in the past 
strongly conditions learning opportunities.  
Companies tend to develop new knowledge in domains in which 
they already possess competencies (Teece, 1986), thus preferring to 
exploit a technological domain rather than exploring a new one. When 
they understand the need for a new body of knowledge, they start to 
explore new knowledge domains, preferring those that are close to ones 
they currently have at their disposal (Dosi, 1982). 
Industry EXPLOIT EXPLOR 
BP 74.14% 25.86% 
THE 72.22% 27.28% 
Table 5. Technological strategies by industry. 
Only when the analysis is performed at the segment level, specific 
behaviours emerge (Table 6). Indeed, biotech companies are the most 
prone to exploration, while among THE firms only semiconductors 
emerge for their involvement in explorative activities. As a matter of fact, 
the scientific nature of innovation forces BIO companies to explore new 
technological fields, in order to discover new compounds.  
Segment EXPLOIT EXPLOR 
BIO 57.58% 42.43% 
PH 75.62% 24.38% 
CHOE 75.99% 24.01% 
SE 67.85% 32.15% 
TCE 75.85% 24.15% 
Table 6. Technological strategies by industry segment. 
 
Regarding SE firms, exploration is required in order to acquire 
competencies in new industries in which they aim at entering, such as 
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the automotive one, to provide their skills on chips and integrated circuits 




4.3 Technological specialization 
As to technological specialization, BP firms mostly tend to 
concentrate patenting activity within a familiar and crucial 
technological field (i.e. core knowledge domain). On the other hand, in 
the THE industry the capability to recombine and integrate pieces of 
knowledge belonging to different knowledge domains is primarily critical 
and leads to a higher breadth of technological fields involved in the 
development, thus, reducing the average relevance of each CPC 
(Table 7). Since the production in the THE industry often requires electrical 
and software engineering competencies and the integration with a 
variety of components, companies may require knowledge on multiple 
technologies to work effectively with their suppliers (Brusoni et al., 2001). 
On the contrary, BP companies are involved in very risky R&D processes 
that are extremely expensive, take a very long time and have high failure 
rates (Mazzucato and Tancioni, 2012). Therefore, they are forced to 
conduct a “guided search”, typified by more scale economies in R&D 
and path-dependency (Gambardella, 1995), and concentrate their 
activities towards skills that are essential for their survival. 
Industry CORE NONCORE 
BP 32.27% 67.74% 
THE 24.98% 75.02% 
Table 7. Technological specialization by industry. 
At the segment level, the focalization on core knowledge fields is 
much evident for biotech companies (Table 8).  
Segment CORE NONCORE 
BIO 60.32% 39.70% 
PH 29.76% 70.24% 
CHOE 20.39% 79.61% 
SE 30.78% 69.22% 
TCE 19.89% 80.11% 
Table 8. Technological specialization by industry segment. 
Indeed, in such segment companies have to face many 
challenges, such as R&D, capital, business development, manufacturing 
and sales issues, which force them to concentrate their R&D efforts on 
few knowledge fields. As to the THE industry, SE firms exhibit higher levels 
of specialization. Such strategy depends on the technological 
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complexity of semiconductors, which forces them to focus mainly on few 
domains and carry out a specialization strategy. Regarding PH, CHOE 
and TCE firms, they tend to pursue a diversification strategy, extending 
their business on a wide range of technological fields. Actually, they 




4.4 Openness of the innovation process 
The closed approach is the strategy more frequently adopted and, 
in both industries, covers almost totally R&D efforts (Table 9). For instance, 
in the THE sector companies choose a CI strategy to speed up their R&D 
processes, being development pace faster and product life cycles 
shorter. R&D collaborations in such industry cover a small share of 
innovative activities and are pursued for two main purposes: 
• collaborations with other companies, such as SE ones, are 
necessary since partners manufacture parts, components and 
products that are incorporated into firms’ products and, then, the 
joint development may improve the overall quality and 
innovativeness perceived by their customers. Indeed, among THE 
firms semiconductors display the higher level of R&D 
collaboration(Table 10); 
• R&D partnerships with external firms are stipulated in order to set 
regulations and industry standards for a particular technology. For 
instance, it is the case of the computer hardware, where firms 
define together standards for ports, interfaces, specifications, 
network architectures, data channels, platform modules. 
Regarding companies belonging to the BP industry, they exhibit the 
higher level of openness, since the integral nature of innovation that 
features the industry forces them to outsource shares of long, risky and 
expensive activities and collaborate in order to reduce the overall R&D 
effort. As a matter of fact, since no single firm possesses all the 
knowledge, skills and techniques required (Powell et al., 1996), the 
collaboration results from the need for complementary expertise. The BP 
industry is featured by the highest rate of joint patenting activities (Kim 
and Song, 2007) and OI is seen not only as an innovation strategy, but 
also as the very core business model for many companies, especially for 
biotech ones. Indeed, most of them do not sell products, but rather enter 
into collaboration agreements with other BP companies. Such behaviour 
features specifically small biotech firms collaborating with large 
pharmaceutical ones.  
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Industry CLOSED OPEN_SCI OPEN_IND 
BP 96,60% 1,40% 2,00% 
THE 98,79% 0,13% 1,09% 
Table 9. Open innovation adoption by industry 
Segment CLOSED OPEN_SCI OPEN_IND 
BIO 93.10% 3.23% 3.66% 
PH 96.92% 1.23% 1.85% 
CHOE 99.42% 0.12% 0.47% 
SE 97.82% 0.21% 1.97% 
TCE 99.73% 0.01% 0.25% 
Table 10. Open innovation adoption by industry segment. 
A final remark concerns the adoption of R&D collaboration 
strategies with scientific partners. In both industries, I uncovered a higher 
propensity to industrial partnerships, probably because of the features of 
the investigated sectors. However, BIO companies exhibit the highest 
level of collaboration with scientific entities. Indeed, they tend to show 
strong reliance on new discoveries and adaptations made in specialized 
labs and hence are likely to show high R&D collaboration. Medical 
innovations have based extensively on activities made possible by 
interdisciplinary flows of knowledge with life and physical sciences 
playing key roles. In many cases, BIO companies originate from 
knowledge spillovers and discoveries within universities and research 
centres; therefore, they have a natural attitude towards partnerships with 
scientific entities. In the BP industry, the reason for collaboration with R&D 
scientific partners include: 
• transfer of technology; 
• technological/consulting advice; 
• technological information absorption; 
• access to information on engineers, scientist and trends in R&D; 
• research contracts to complement firm R&D; 
• research that the firm cannot perform; 
• graduate recruitment for supporting R&D activities; 
• use of other scientific resources; 
• product/process testing; 
• quality control improvement. 
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Regarding THE firms, since they are engaged in standardized 
product assembly and fast R&D, the large learning process required for 
partnerships with scientific entities and the fact that the results obtained 
are, in many cases, not directly exploitable for business applications 
reduce the propensity to such kind of collaboration.  
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4.5 Type of innovation 
From the combination of the novelty level of the technology and 
the impact on the linkages between components, I defined for each 
patent the type of innovation inherent in the application. Table 11 
displays the shares of such types of innovation detected within the 
documents filed by the companies belonging to the sample. In both 
industries, architectural innovations are most frequent.  
Industry INCR MOD ARCH RAD 
BP 30.31% 19.35% 37.28% 13.05% 
THE 44.43% 4.75% 45.65% 5.17% 
Table 11. Types of innovation by industry. 
Since I investigated only priority patents, a new patent family is in 
many cases originated from the creation of new combinations of 
components and concepts, without using new disruptive technologies. 
The second type of innovation that features both industries is the 
incremental one, more markedly among THE firms. Then, considering that 
incremental and architectural innovations are based on the 
reinforcement of core concepts, I deduce that such strategy is the most 
pursued in these two science-based sectors. As to modular and radical 
innovation, I discovered the higher propensity to such types of innovation 
among BP firms.  
Given that the nature of products developed by such industries is 
opposite (i.e. integral in the BP sector and modular in the THE one), I 
further investigate how firms achieve each type of innovation, in order 
to validate my operationalization and give an industry-specific 
interpretation to each one. For the BP industry, I started from the “new 
drug classification” provided by the Food and Drug Administration (FDA). 
Actually, FDA labels new drugs along two dimensions at the time of 
approval: therapeutical potential and chemical composition. On the 
basis of their therapeutical potential, drugs are classified into two classes: 
“priority review” drugs, which represent a therapeutical advance over 
available therapy, and “standard review” drugs, which have 
therapeutical qualities similar to those of an already marketed drug. 
Based on their chemical composition, drugs are classified as either new 
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molecular entities (NMEs) or “old” drugs that either are new formulations 
or have new indications of use. The NMEs are the most technologically 
advanced products, because they are based on an active ingredient 
that has never been marketed before. Conceptually speaking, the two 
dimensions of the FDA classification coincide precisely with the two 
dimensions in my classification of types of innovation (Figure 14). 
Specifically, the FDA’s therapeutical potential dimension corresponds to 
the “core concepts” dimension and the chemical composition 
dimension corresponds to “linkages between components” one (i.e. a 
new chemical composition can be seen as a new architecture). 
Therefore, a radical innovation involves products with a substantially new 
composition and appears to represent an advance over available 
therapy. A modular innovation provides significantly greater benefits, but 
the composition is not considerably new. An architectural innovation 
uses a substantially different composition than existing products but 
appears to have therapeutical qualities similar to those of an already 
marketed drug. An incremental innovation consists only on the 
improvement of a specific drug in terms of limited advancements in 
safety and efficacy, but BP firms depend on incremental innovations to 
provide the revenue that will support the development of more risky 
radical drugs.  
 
Figure 14. Types of innovation in the BP industry. 
As to the THE industry, the labelling is simpler, being products 
featured by modularity of design. Actually, firms assemble modules, 
components and parts in order to build the product/hardware 
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architecture. Innovation is then achieved employing two kinds of 
knowledge, the component knowledge and the architectural one 
(Figure 15). Therefore: 
• incremental innovation refines and extends an established 
hardware design. Improvement occurs in individual components, 
but the architecture remain the same; 
• modular innovation changes, replaces components without 
changing the product’s architecture. Therefore, the innovation 
relates to the introduction of new component knowledge in 
already existing architectures, since the technological novelty is 
concentrated to these parts; 
• architectural innovation is the reconfiguration of an established 
hardware system to link together existing components in a new 
way. This does not mean that the components themselves are 
untouched by architectural innovation, since a change in a 
component (i.e. size or some other subsidiary parameters) that 
creates new interactions and new linkages with other 
components in the established technology may be required. The 
important point is that the component knowledge, and the 
associated scientific and engineering knowledge, remain the 
same; 
• radical innovation establishes a new design and, hence, a new 
component knowledge embodied in hardware components that 
are linked together in a new architecture. Thus, such type of 
innovation destroys the usefulness of both previous architectural 




Figure 15. Types of innovation in the THE industry. 
A further remark regards radical innovation, since it is the most 
difficult type of innovation to achieve. Considering the results at the 
segment level (Table 12), it is possible to appreciate the differences 
among companies belonging to different segments. In the BP industry, 
BIO firms emerge for their capability to obtain radical innovations, which 
is innate in their business. Among THE companies, TCE ones exhibit the 
higher shares of RAD, thus signalling the vivacity that has always 
characterized the segment. In general, TCE firms are more prone to 
architectural innovations than other segments, while CHOE companies 
are featured by incremental innovation strategies. Such behaviour is still 
evident in an industry where new dominant designs are difficult to 
establish and companies are focused on achieving economies of scale 
in production. Finally, the segment showing the highest share of modular 
innovations is the pharmaceutical, with firms obtaining an advance over 
available therapy with already existing compositions. 
Segment INCR MOD ARCH RAD 
BIO 30.17% 15.95% 37.07% 16.81% 
PH 30.33% 19.65% 37.30% 12.72% 
CHOE 51.21% 4.20% 41.32% 3.28% 
SE 46.23% 4.27% 45.08% 4.41% 
TCE 37.35% 5.80% 49.35% 7.50% 
Table 12. Types of innovation by industry segment.  
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4.6 Quality of innovation output 
Given that only the potential quality of a technology is embedded 
within the concept of type of innovation, the last dimension (i.e. quality 
of innovation output) investigates the effective contribution of new 
inventions to companies’ business in terms of technological 
acknowledgement and marketability. Table 13 shows the quality of 
innovation output by industry: for THE firms I uncovered a larger share of 
HIGH patents (i.e. patent exhibiting both market and technological 
quality) compared to BP firms. Specifically, such behaviour can be 
interpreted with these considerations about the BP industry: 
• since a patent is filed before the drug is subject to the 
evaluation of public health authorities and clinical tests have 
proved its therapeutical quality, the likelihood of further 
abandonment is higher. Therefore, in the BP industry the 
share of lapsed patent affects the quality I detected; 
• since MARK is higher in the BP industry, for many patents high 
quality has been not achieved because of the lack of 
technological acknowledgement. This is in line with the 
integral nature of products developed in such sector. Each 
compound is covered by few patents, each patent protect 
a “formula” (i.e. a composition), therefore its’ very hard to 
be further cited and technologically acknowledged by third 
parties. Furthermore, it is simpler for inventions within the THE 
industry, which are related to application science and 
engineering, be useful for the technological progress and 
serve as the basis for subsequent technological 
development, even in other industries. 
Industry LOW TECH MARK HIGH 
BP 20.69% 0.96% 19.10% 59.25% 
THE 5.22% 0.93% 8.02% 85.83% 
Table 13. Quality of innovation output by industry. 
Investigating the quality of innovation output by industry segment 
(Table 14), I uncovered that CHOE firms exhibit the highest rates of HIGH; 
therefore, patents in such segment are featured by marketability and 
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technological acknowledgment. Among firms within the BP industry, PH 
ones show the larger share of low quality applications, while MARK is 
relevant for BIO firms, thus signalling that in the segment is vital to create 
a new patent family and aim at the international diffusion.  
Segment LOW TECH MARK HIGH 
BIO 15.09% 2.16% 21.98% 60.78% 
PH 21.19% 0.85% 18.84% 59.11% 
CHOE 1.44% 0.76% 9.34% 88.46% 
SE 3.90% 0.29% 9.22% 86.59% 
TCE 9.60% 1.93% 5.46% 83.01% 
Table 14. Quality of innovation output by industry segment.  
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4.7 Correlation analyses  
The purpose of this section is to show the results of correlation 
analyses performed for the two industries. The aim is to investigate the 
relationships among the variables summarising the five dimension of 
innovation taken into account in my thesis. First, it is necessary to 
underline that innovation is a complex topic, which is affected by many 
issues and can be considered as the result of business strategies involving 
many units, functions and management decisions. Therefore, it is not 
possible with few variables and five dimensions define the perfect 
“formula” for successful innovations. The purpose of the section is to 
delineate which behaviours are related to best outputs and outcomes in 
each industry under investigation.  
Regarding the BP industry, Pearson’s correlation coefficients 
among the variables under investigation in Table 15 indicate that: 
• high quality innovations are positively correlated to 
architectural innovations and negatively to modular ones, 
therefore investing on new compositions that have 
therapeutical qualities similar to those of already marketed 
drugs is the best strategy for successful innovations; 
• incremental inventions negatively correlate with low quality 
outcomes, therefore focusing only on improvements on 
existing solutions will reduce the likelihood of failure; 
• opening up the R&D processes and collaborating with 
industrial partners lead to architectural innovations, which 
are acknowledged by the scientific community but not by 
the market. On the contrary, closed innovation strategies 
negatively affect the technological quality of an invention; 
• among technological strategies, exploitation ones are 
positively correlated to architectural innovations, therefore 
firms exploit already owned knowledge in order to develop 
new compositions; 
• companies pursuing a focalization strategy are more prone 
to open up their R&D processes and collaborate with 
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industrial partners, providing their specialization and 
accessing to complementary expertise; 
• the focalization is negatively correlated to incremental 
inventions, therefore firms pursuing a specialization strategy 








Note: ** the correlation is significant at 0.01 level, * the correlation is significant at 0.05 level 
Table 15. Pearson’s correlation coefficients for the BP industry. 
 
  1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 
1. CORE 1 -1.000** .417** -.417** -0.148 -0.039 .251* -.253* 0.183 0.141 -0.051 -0.132 0.18 0.109 -0.023 
2. NONCORE  1 -.417** .417** 0.148 0.039 -.251* .253* -0.183 -0.141 0.051 0.132 -0.18 -0.109 0.023 
3. EXPLOIT   1 -1.000** -0.056 0.05 0.028 -0.167 0.058 .228* -0.098 -0.126 0.164 0.04 0.032 
4. EXPLOR    1 0.056 -0.05 -0.028 0.167 -0.058 -.228* 0.098 0.126 -0.164 -0.04 -0.032 
5. CLOSED     1 -.712** -.678** -0.016 -0.022 -0.134 0.19 0.196 -.455** -0.046 0.009 
6. OPEN_SCI      1 -0.033 0.087 0.12 -0.139 -0.116 -0.159 -0.026 0.153 0.042 
7. OPEN_IND       1 -0.068 -0.094 .337** -0.149 -0.113 .674** -0.094 -0.057 
8. INCR        1 -.524** -0.196 -.430** -.255* -0.116 0.156 0.165 
9. MOD         1 -.427** -0.127 .340** -0.112 0.041 -.323** 
10. ARCH          1 -.265* -.260* .361** -.250* .322** 
11. RAD           1 0.177 -0.09 0.01 -0.147 
12. LOW            1 -0.079 -.368** -.650** 
13. TECH             1 -0.134 -0.174 
14. MARK              1 -.388** 
15. HIGH               1 
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As to the THE industry (Table 16), I uncovered: 
• a positive relationship between high quality and focalization 
strategies, thus signalling that firms not dispersing their efforts on a 
wide range of knowledge fields are likely to achieve successful 
innovations; 
• a positive correlation between high quality and exploitation 
strategies, therefore avoiding to explore technological domains in 
which firms lack of prior familiarity will lead to best outcomes; 
• that closed innovation strategies correlate with high quality, thus 
firms gain competitive advantage by internally developing their 
technologies; 
• that radical innovations are positively correlated to focalization 
strategies, i.e. firms concentrating their efforts develop high-
potential technologies which depart significantly from past 
practices; 
• a negative relationship between R&D collaboration with industrial 
partners and high quality, signalling that firms are unable to 
employ the results obtained from the joint development for 
improve their business. Actually, R&D collaborations need time to 
build up and generate long-term benefits, therefore aren’t 
suitable in industries featured by fast development pace, shorter 
product life cycles and rapid changes in the market; 
• a positive relationship between modular innovations and 
marketability, thus the overturning of some components within a 
consolidated architecture lead to new opportunities of 
development for “old” patent families that are not useful for the 
scientific community; 
• a positive correlation between architectural innovation and 
technological acknowledgement, signalling that new hardware 
architectures are further adopted and have an utility on the path 
of the technological progress, even though the new patent family 








Note: ** the correlation is significant at 0.01 level, * the correlation is significant at 0.05 level 
Table 16. Pearson’s correlation coefficients for the THE industry. 
  
  1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 
1. CORE 1 -1.000** .469** -.469** 0.029 -0.008 -0.028 0.024 -0.121 -0.004 .176* -.176* -0.113 -0.134 .248** 
2. NONCORE  1 -.469** .469** -0.029 0.008 0.028 -0.024 0.121 0.004 -.176* .176* 0.113 0.134 -.248** 
3. EXPLOIT   1 -1.000** 0.162 -0.118 -0.142 0.074 -0.128 -0.024 0.099 -.214** -0.083 -0.027 .214** 
4. EXPLOR    1 -0.162 0.118 0.142 -0.074 0.128 0.024 -0.099 .214** 0.083 0.027 -.214** 
5. CLOSED     1 -.304** -.975** -0.115 0.102 0.082 -0.101 -.281** -0.001 -0.049 .251** 
6. OPEN_SCI      1 0.086 0.055 -0.058 -0.043 0.078 0.077 -0.011 -0.046 -0.035 
7. OPEN_IND       1 0.108 -0.093 -0.076 0.088 .276** 0.003 0.062 -.255** 
8. INCR        1 -.299** -.720** -.264** -0.062 -0.148 -0.011 0.105 
9. MOD         1 -.376** 0.103 -0.098 -0.046 .281** -0.049 
10. ARCH          1 -0.129 0.156 .195* -0.143 -0.117 
11. RAD           1 -0.096 -0.055 -0.077 0.136 
12. LOW            1 0.007 -0.011 -.801** 
13. TECH             1 -0.045 -.318** 
14. MARK              1 -.487** 




My PhD thesis aims at contributing to the debate on knowledge 
and innovation management by suggesting a framework for analysing 
five dimensions of innovation. First, the study of innovation strategies 
requires some peculiarities: 
• the use of standardized data, such as patent documents, 
allowing to access information about the whole population 
of innovating firms, since without data regarding all 
inventions it is unable to absolutely define, for instance, the 
novelty level of technologies, components and 
architectures; 
• the use of continuously updated data, like patents, since all 
inventions require time to be acknowledged and adopted 
by the scientific community and other inventors, therefore 
ex-post information are necessary; 
• the assurance that the information has been validated by 
third parties, like patent examiners, allowing to consider 
patent data as objective; 
• the need for a multidimensional perspective, since R&D 
development and innovation processes are complex and 
require a wider overview; 
• the necessity to take into account the peculiarities of R&D 
processes of the industry under investigation, e.g. adapting 
some operationalisations of variables, and, in addition, the 
necessity to separate the analysis if more than one industry 
is studied;  
From the analysis of the results, it appears that some are in line with 
the scientific literature, while others are industry-specific.  
By investigating exploitation vs. exploration strategies, I evaluated 
the share of each strategy on the overall innovation strategy pursued by 
companies, confirming that exploitation strongly prevails on exploration 
(Dosi, 1982; Teece, 1986). Even though companies are ambidextrous and 
the two strategies can coexist inside them (March, 1991; Levinthal and 
75 
 
March, 1993; March, 1996; Tushman and O’Reilly, 1996; Benner and 
Tushman, 2003; He and Wong, 2004; March, 2006), they cannot within a 
specific knowledge domain (Burgelman, 2002; Gupta et al., 2006).  
Regarding technological specialization, in both industries I found a 
positive correlation between specialization and exploitation. This 
confirms that companies at least progressively modify their innovation 
strategy, avoiding to concentrate a relevant share of R&D activities on 
previously unexplored domains. In general, industry-specific features, as 
already discussed in this work, affect the specialization vs. differentiation 
strategy. 
As to OI strategies, the highest levels of openness were detected 
for BIO firms (about 7%), in line with the real features of the industry 
segment. In general, the BP sector exhibits the higher share of OI 
adoption, as already uncovered by scientific literature (Kim and Song, 
2007). Regarding the partner typology, no specific behaviours related to 
partnerships with scientific entities were uncovered, while R&D 
collaborations with industrial partners have positive effects only in the BP 
industry. 
Regarding the type of innovation, an effort for the industry-specific 
interpretation of the Henderson and Clark (1990) matrix has proved the 
application of my operationalization to both sectors. Even though in the 
analysed industries I uncovered the preponderance of architectural 
innovations, specific behaviours and correlations emerge. For instance, 
BP firms are more prone to radical and modular innovations, while THE 
ones mostly focus on incremental inventions.  
As to the quality of innovation output, for THE firms it is simpler to 
achieve high quality inventions, while in the BP industry many difficulties 
emerge. Since the economic value of each successful patent in the BP 
sector is clearly higher, the likelihood of success for a patent is lower.  
Finally, correlation analyses demonstrate the effect of industry-
specific features on innovation strategies adopted. Only two correlations 
were confirmed for both industries (i.e. the positive correlation between 
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CORE and EXPLOIT and the positive relationship between ARCH and 
TECH). Radical innovations are related to focalization strategies in the 
THE industry, while no correlation was uncovered for BP firms. 
Furthermore, high quality innovations are correlated with core, 
exploitation and closed strategies in the THE sector, and only with 





In this final chapter, I present an overview of the theoretical and 
managerial implications of the work, as well as of the limitations and the 
future research lines and challenges.  
5.1 General contributions 
I aim at contributing to the current debate on knowledge and 
innovation management by providing a patent-based framework, 
which detects five dimensions of innovation processes and describes 
how companies organize R&D activities and achieve high quality 
inventions from a quantitative point of view.  
Since innovation processes are featured by extreme complexity, I 
believe that only multidimensional approaches may better summarize 
innovative behaviours. The analysis is performed at the knowledge 
domain level, since the variables under investigation derive from both 
direct information disclosed in patent documents and in depth studies 
on technological domains declared in such documents.  
I draw on objective data gathered from PATSTAT database and 
started from variables already acknowledged and operationalized by 
scholars, improving, adapting and mixing them. As widely described in 
Appendix A, this work is the result of a detailed study of PATSTAT 
database, which consists of more than 20 tables and about 500 
Gigabytes of data. The methodology and the operationalisation I 
defined were implemented in a software, which is currently in use at the 
University of Salerno.  
An industry-level analysis on a sample of about 23,000 patent 
applications and 223 R&D intense companies from BP and THE industries 
was performed, considering patent applications from 2003 to 2005, 
validating both the framework applicability and its explicative power 
and usefulness. Many differences in the adoption of innovation strategies 




In what follows, the main contributions of the thesis are summarized, 
distinguishing between implications for theory and practice.  
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5.2 Theoretical contributions 
In this work, I performed a wide literature review aiming at defining 
which dimensions of innovation were mainly investigated by scholars. 
Considering the large number of papers and contributions in the field of 
knowledge and innovation management, I tried to summarise their 
findings in order to define for each dimension opposite concepts to 
consider in my framework (e.g. exploitation vs. exploration strategy for 
the dimension “technological strategy”). 
Furthermore, from the literature review on the operationalisations 
mainly acknowledged by scholars I found the relationship between 
patent data and each dimension of innovation. I critically analysed such 
metrics and derived new variables from patent data by improving, 
adapting and mixing those previously adopted in literature.  
Hence, the former theoretical contribution concerns the definition 
of an integrated patent-based framework, which investigates five 
dimensions of innovation in order to define innovation strategies carried 
out by firms. Despite innovation strategies are widely studied in literature, 
most attention has been devoted to only one dimension of R&D 
processes at time. Since innovation processes are featured by extreme 
complexity, I suggest a multidimensional approach, which provides a 
more complete overview of such processes. 
Additional theoretical contribution derive from the analysis of 
specific dimensions. For instance, a contribution pertains to the definition 
of radical innovation. In my opinion, a distinction between potential 
radicalness of an invention and real breakthrough is necessary: actually, 
I derive information about the output of the R&D process from the 
concept of “type of innovation”, with companies aiming, for instance, at 
achieving a radical innovation. Hence, the metric takes into account ex-
ante information declared by the company during the application, i.e. 
defining a potential radicalness. Conversely, the real outcome of the 
patent can be better measured, according to Arts et al. (2013), through 
ex-post indicators, which reflect the impact and value of inventions.  
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Regarding the types of innovation, my work contributes to the 
understanding of the difference between radical vs. incremental 
innovation and exploration vs. exploitation strategy. During my literature 
review, I uncovered that some scholars use indiscriminately the concept 
of radical innovation and exploration strategy. Actually, in these works 
scholars underline that the exploration strategy will lead to radical 
innovation, while by exploiting the knowledge already owned firms 
obtain incremental innovation. My work demonstrates that there is no 
direct relationship. This means that also exploitation strategies may result 
in radical outputs. For instance, in the BP industry biotech firms employ 
the few knowledge fields they control in order to obtain potentially novel 
solutions. 
Furthermore, unlike other scholars analyzing exploitation vs. 
exploration activities, I decided to modify the value of the experience 
period (i.e. 5 years), since I believe that it is industry-specific. By 
considering a time span adjustment factor I take into account the 
different features of the belonging sector of companies and such 
assumption affects the labelling activity of each technological field 
owned by firms. 
A further theoretical contribution concerns the focus on 
technological specialization. Actually, I found few contributions 
regarding specialization vs. differentiation strategies, even though the 
familiarity of a knowledge field is a key element for R&D processes.  
Regarding the openness dimension, I contributed to the wide 
literature on open innovation by demonstrating that patent data can be 
useful for detecting R&D collaborations among firms. Therefore, joint 
patents can be employed for determining the weight and the impact of 
OI adoption on the overall innovation strategy pursued by firms. 
As to the four types of innovation, I believe that the 
operationalization provided can be considered an interesting 
contribution, since it recovers the acknowledged matrix provided by 
Henderson and Clark in 1990 and defines two variables deriving from 
patent data in order to schematize the novelty level and the linkage 
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between concepts and components. Since such levels are investigated 
through patent data, the focal patent is really compared to all the other 
patent inventions in order to define, for instance, whether it is effectively 
potentially and universally radical. An interesting contribution regards the 
operationalization of components: I used Cooperative Patent 
Classification codes in order to define concepts and components and 
their combination to schematize an architecture.  
Finally, regarding the quality of innovation output, unlike many 
literature contributions, I defined the quality of innovation output as a 
combination of technological and market impact. Therefore, I believe 
that the matrix I developed may be the basis for future investigations.  
82 
 
5.3 Practical contributions 
I provide a methodology investigating innovation strategies on the 
basis of the study of patent applications, by using information disclosed 
in data recorded in PATSTAT database. The advantages in employing 
patent data in my study are various: 
• they are a direct outcome of R&D efforts, and of those inventions 
which firms expect may have a commercial impact and provide 
benefits that outweigh costs for obtaining intellectual property 
protection; 
• they contain highly detailed information on content and 
ownership of patented technology;  
• they cover a broad range of technologies. 
Given the availability and objectivity of patent documents, 
studying innovation through the analysis of patent data can help 
decision-makers to: 
• assess the status of firms’ innovation strategies; 
• monitor the innovation strategy of the company, tracing both its 
history and evolution within each of the five dimensions. In this 
way, managers can deal with the challenge of adoption of 
specific behaviours in their organizations, and make direct 
improvements, evaluating firm’s performance in relation to each 
one; 
• know which innovation-related items to manipulate to improve 
the effectiveness of innovation strategies; 
• compare innovation strategies over time and space; 
• benchmark with competitors. Given the availability and 
objectivity of patent data, the framework can be used as a 
method of comparability, enabling managers to position their 
organizations against competitors through a benchmark of 
innovation strategies. 
Moreover, the methodology may be applied at patent-, firm- and 
industry-level analyses, providing business analysts a practical instrument 
for detecting the innovation strategies carried out by companies and 
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investigating the impact of specific behaviors on economic and 




Some limitations can be outlined for the work. Firstly, the use of 
patenting information as a proxy of inventive activities might 
underestimate the phenomenon, since not all R&D efforts will result in an 
application for a patent. Secondly, the research is confined to top R&D 
spending companies; hence, the findings may not provide a general 
overview of BP and THE industry as a whole, even though the sample 
under investigation covers a relevant share of patenting activities within 
the belonging sector. Thirdly, the use of patent data for investigating the 
adoption of OI could be questionable, since not all R&D collaborations 
can be captured by co-patenting activities (Hagedoorn et al., 2003); this 
may lead to the underestimation of OI activities. Finally, not all 
technological inventions are patented and patent propensities vary 
across firms and industries, even though in sectors characterized by 
intense R&D efforts, like BP and THE ones, patents are used as a means 
of appropriation of innovation (Pavitt, 1984). This leads to the 
consideration that my framework may not be useful for analysing 
innovation in all industries. 
Other limitations are related to the operationalization of patent 
information stored in PATSTAT database. For instance: 
• as explained in Appendix A, the patents owned by the 
investigated firms were detected searching on PATSTAT the 
names of the parent company and their subsidiaries. Therefore, 
typing mistakes in person fields within PATSTAT impede the linking 
between applicants and companies belonging to the sample, 
thus, some patent applications may have been missed; 
• some documents are excluded from the analysis since they did 
not contain a CPC code;  
• the results found in the analysis of technological and 
specialization strategies are affected by the definition of core and 
non-core technological fields and, in particular, by the decision 
of cutting CPCs without considering the sub-group number, in 
order to avoid excessive detail on the definition of the knowledge 
domains owned by companies. 
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This last consideration suggests a deepening of the 
operationalization of knowledge domain level variables, e.g. building a 
statistical model in order to define for each industry the proper time 
spans, rather than identifying them through the analysis of the 
characteristics of R&D processes.  
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5.5 Future research directions 
In this section, I show some open research lines and challenges for 
future reference. In fact, the concepts and ideas that were adopted 
and implemented in this thesis can be used as a basis for a variety of 
aspects of future work. 
Firstly, future research will be addressed to widening the sample of 
investigation and examining different industries. In addition, it is possible 
to extend the number of dimensions, e.g. adding other variables from 
data available or derivable from PATSTAT, such as: 
• the diversity of technological fields involved in the invention; 
• the typology of the business units which developed the new 
technology (i.e. parent company, subsidiary, previously acquired 
or merged unit); 
• the technological strategies carried out by partners within the 
knowledge fields involved in R&D collaborations; 
• the scientific complexity of the innovation, which can be 
measured through non-patent literature cited by the focal 
patent; 
• the impact of external inventors coming from industrial or scientific 
communities; 
In addition, by defining a set of CPCs describing a specific industry, 
it is possible to go beyond the definition of a sample and analyze the 
whole industry. This word requires only the development of a new 
programming code. 
Furthermore, the results provided by the framework need to be 
validated through case studies on companies belonging to the sample 
and compared or correlated with other databases and sources 
available, such as annual reports and financial data. 
Finally, I plan to apply the content analysis to my framework, in 
order to replace the CPCs with keywords detected from patents’ 
abstracts. This will improve these dimensions: 
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• technological strategy and technological specialization, since 
each keyword may define a knowledge domain; 
• type of innovation, since the combination of keywords detected 
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APPENDIX A. PATSTAT database, data collection and 
example of framework application 
 
The purpose of this section is to illustrate how information from 
PATSTAT database has been employed in order to collect data and 
implement the patent-based framework.      
 PATSTAT contains bibliographical and legal status patent data 
relating to more than 90 million patent documents from over 100 
countries, collected by the European Patent Office (EPO). This is 
extracted from the EPO’s databases and is provided as raw data for 
statistical tools. Raw data contain 220 Gigabytes of information, which 
reach about 500 Gigabytes considering the addition of new tables and 
variables I made in order to adequate such data to my research 
purposes and the space dedicated to MySQL database, on which I 
imported raw data and implemented my tool.  
The interface used for the tool is web-based, built on a LAMP 
platform (Linux, Apache, MySQL and PHP) and the open source software 
XAMPP for Windows. The programming code was developed using HTML, 
CSS, JAVA and primarily PHP scripts and a considerable commitment 
was required to write about 50,000 lines of code used to manage the 
database and collect data. 
In what follows I show an example of data collection and 
management considering the information extracted for Zeltia, a Spanish 
pharmaceutical company that operates through a variety of subsidiaries 
within the bio-pharmaceutical industry. Until 2007, Zeltia's research 
activities in the pharmaceutical area had not resulted in a marketed 
product.  
The first step of the work is the download of the list of subsidiaries 
from firm’s 2011 annual report. These are the units disclosed in such 
document: 
• Pharma Mar, S.A.U.; 
• Genómica, S.A.U.; 
• Zelnova, S.A.;  
• Protección de Maderas, S.A.U.;  
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• Xylazel, S.A.; 
• Pharma Mar USA; 
• Pharma Mar AG (Switzerland); 
• Pharma Mar SARL (France); 
• Pharma Mar GmbH (Germany); 
• Pharma Mar Ltd (UK);  
• Copyr, S.p.A. (Italy);  
• Promaxsa Protección de Maderas, S.L.U.; 
• Sylentis, S.A.. 
For each subsidiary, I searched more information, in order to verify 
the occurrence of units merged or acquired by other companies. 
Actually, only patent applications filed after the merge/acquisition were 
considered in the analysis, therefore I recorded the eventual year of the 
merge/acquisition event. In the case of Zeltia, all the units are direct 
subsidiaries established by the company group itself.  
For each subsidiary a research on the table tls206_person in PATSTAT 
was performed, aiming at finding the records containing the name of 
each unit in the field person_name and resulting in the following list of 
distinct names: 
• GENOMICA S.A.U; 
• GENOMICA S.A.U.; 
• GENOMICA S.A.V; 
• NOSCIRA S.A.; 
• NOSCIRA, S. A.; 
• NOSCIRA, S.A.; 
• PHARMA MAR; 
• PHARMA MAR S. A.; 
• PHARMA MAR S. A. SOC UNIPERSONAL; 
• PHARMA MAR S. A. U.; 
• PHARMA MAR S.A; 
• PHARMA MAR S.A SOCIEDAD UNIPERSONAL; 
• Pharma Mar S.A.; 
• PHARMA MAR S.A. SOCIEDAD UNIPERSONAL; 
• Pharma Mar S.A., Sociedad Unipersonal; 
• PHARMA MAR S.A., SOCIEDAD UNIPERSONAL.; 
• PHARMA MAR S.A.SOCIEDAD UNIPERSONAL; 
• Pharma Mar S.A.U.; 
• PHARMA MAR S.A.U., COLMENAR VIEJO; 
• PHARMA MAR SA; 
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• PHARMA MAR SA SOC UNIPERSONAL; 
• PHARMA MAR SAU; 
• PHARMA MAR, S; 
• PHARMA MAR, S. A. U.; 
• PHARMA MAR, S.A; 
• PHARMA MAR, S.A.; 
• Pharma Mar, S.A. Sociedad Unipersonal; 
• Pharma Mar, S.A., a Madrid, Spain corporation; 
• PHARMA MAR, S.A., SOCIEDAD UNIPERSONAL; 
• PHARMA MAR, S.A..U.; 
• Pharma Mar, S.A.U.; 
• PHARMA MAR,S.A.; 
• PharmaMar; 
• PharmaMar, s.a.; 
• SYLENTIS S. A.; 
• Sylentis S.A.; 
• Sylentis S.A.U.. 
The example provides a clear understanding about the lack of 
unique correspondence between the name of a subsidiary and the 
records in the table tls206_person. Actually, many records were found for 
each subsidiary, and occasionally the names are affected by typing 
errors, since EPO recorded information in PATSTAT database with 
automatic procedures, which detect text through optical character 
recognition (OCR) software. Nevertheless, often PATSTAT relates such 
person_name field to a standardized name reported in table 
tls208_doc_std_nms, therefore each standardized name is linked to a 
wide number of records in the table tls206_person, which can be rapidly 
assigned to the firm. Actually, the process starts with the search within the 
standardized names and ends with a further research among the 
residual records, which are not yet linked to the company. 
At the end of the process, all the “person names” related to Zeltia 
were recorded and assigned with the firm. Thus, a first list of patent 
applications can be defined by extracting data from the table 
tls201_appln. The list consists of 360 patent applications from 2003 to 2005, 
but only 8 documents are related to priority patent applications filed in 
EPO, United States Patent Office (USPTO) or WIPO (World Intellectual 
Property Organization). The other documents are: 
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• subsequent filings aiming at extending the protection in other 
countries; 
• application continuations to pursue additional claims to an 
invention already filed in a parent application; 
• priority filings not recorded in EPO, USPTO or WIPO, excluded since 
information recorded in other offices lack of some data, such as 
citations; 
• applications without CPCs recorded in the table 
tls224_appln_cpc, which joins the table tls201_appln – containing 
patent applications – with the technological classes affected by 
the invention; 
• subsequent filings necessary to complete the process of approval 
and provide further information to examiners. 
The 8 priority patents can be detected by linking the information 
from table tls201_appln with the priority applications disclosed in table 
tls219_inpadoc_fam, which stores the list of all patent families and their 
parent application (Table 17).  
Application ID Family ID Application number Filing date #CPCs 
209115 143104 EP20030779140 20/10/2003 4 
192977 143104 EP20040714847 26/02/2004 4 
16138696 311134 EP20040720081 12/03/2004 1 
16161426 742363 EP20040768394 09/09/2004 4 
16173267 744877 EP20040798717 15/11/2004 4 
16205256 334715 EP20050075779 04/04/2005 2 
16206407 341717 EP20050077333 12/10/2005 8 
16270510 1850300 EP20050803151 26/10/2005 5 









This is a sample of the SQL query used for extracting the previous 
table: 
SELECT distinct tls201_appln.appln_id, tls219_inpadoc_fam.inpadoc_family_id, 
tls201_appln.appln_id .appln_nr, tls201_appln. appln_filing_date, appln_ncpc 
FROM tls201_appln, tls207_pers_appln, tls206_person, tls219_inpadoc_fam, 
tls204_appln_prior 





tls207_pers_appln.applt_seq_nr>0 and tls207_pers_appln.applt_fake=0 and 
appln_ncpc>0 and yearacquisition_person<= applyear and (appln_auth='WO' or 
appln_auth='EP' or appln_auth='US') and applyear between 2003 and 2005 
ORDER BY tls201_appln. applyear, tls201_appln.appln_id 
 
(the PHP variable $ IDcompany includes an identification number assigned to Zeltia 
and stored in the table tls206_person in order to create a relationships between the 
table and a list of companies under investigation) 
 
Therefore, taking into account only priority documents that meet 
the previous features I reach the final list of 8 inventions developed by 
Zeltia from 2003 to 2005.  
For each document the following information are collected: 
• number of backward citations, by querying the table 
tls212_citation, with the focal patent recorded as the citing 
document. From the count are excluded non-patent 
literature citations; 
• number of 5-year forward citations, as the number of patent 
applications citing the focal patent in the five years following 
its publication, by investigating the table tls212_citation; 
• number of patent assignees, as the number of distinct 
applicants recorded in the patent application. Various 
procedures are required in order to avoid corrupted counts. 
First, if the same company has been recorded more than 
one time within the field (e.g. the patent reports both the 
parent company and a subsidiary), the applicants have 
been considered as an unique entity. Second, in many 
cases in the applicant field were wrongly disclosed inventor 
names. Therefore, I developed an algorithm for removing 
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“fake applicants” from the list, which verify if the item has 
been simultaneously recorded in both applicant and 
inventor lists and remove the inventors from the assignee 
field; 
• family size, as the number of patents declaring the focal 
filing as claimed priority in the five years following its 
application. 
In addition to these variables, other data are extracted from 
PATSTAT, whose operationalization is much complex. The first variable is 
“new combo”, which assumes value 1 if the combination of CPCs 
declared in the patent application can be considered as new (i.e. not 
disclosed in previous documents), otherwise 0. Each CPCs (at level 5) is 
collected from the table tls224_appln_cpc. In order to limit the years of 
investigation and avoid the comparison with obsolete technologies, I 
verified if the same combination occurs in the experience period in all 
patent applications recorded in PATSTAT database. For instance, 
considering that Zeltia belongs to the bio-pharmaceutical industry, I took 
into account all filings from t-1 to t-7, where t is the year of application of 
the focal patent. In order to limit the computational impact of such an 
extended analysis, if the number of CPCs recorded in the focal 
application is less than or equal to 2 the variable “new combo” assumes 
automatically value 0, supposing that a document disclosing at least 2 
classification codes may not cover an invention based on a novel 
architecture.  
A further variable, which requires a specific operationalization, is 
the expiration date of the patent. Actually, in my framework I verify if the 
fees result paid within the eighth year from the first application. In order 
to detect the expiration date I analyse the table tls221_inpadoc_prs 
containing legal status information (i.e. ex-post events that impact on 
the patent). More specifically, the expiration date is the minimum value 
deriving from three searches I made within such table. The first queries 
the field l513ep, which directly contains the expiration date, but it is not 
used by all the patent offices. The second verifies the content recorded 
in the notes to an event. If specific keywords, such as “LAPSED” or 
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“EXPIRED” are reported within the field, I extract the event date and 
assume that it matches with the expiration one. This is a sample of the 
SQL query used for the purpose: 
SELECT min(year(`l525ep`)),min(year(`prs_gazette_date`))  
FROM tls221_inpadoc_prs 
WHERE `appln_id`=$patentID and (`l510ep` LIKE '%LAPSED IN%' or `l510ep`  LIKE '%LAPSE 
DUE TO%' or `l510ep`  LIKE '%LAPSE BECAUSE%' or `l510ep`  LIKE '%LAPSE AS%' or `l510ep`  
LIKE '%LAPSE/EXPIRED%' or `l510ep`  LIKE '%LAPSED THROUGH%' or `l510ep`  LIKE '%HAS 
LAPSED%' or `l510ep`  LIKE '%APPLICATION LAPSED%' or `l510ep`  LIKE '%APPLICATIONS 
LAPSED%' or `l510ep`  LIKE '%EXPIRED ON%' or `l510ep` LIKE '%EXPIRED IN%' or `l510ep` 
LIKE '%WITHDRAW%') 
 
($patentID is the variable containing an identifier of the focal patent) 
 
The third value is derived by employing the field l520ep within the 
legal status in which PATSTAT counts the years from the patent grant. If 
such value is equal to 20, the date of the event is collected. Finally, by 
comparing these three dates, I consider the minimum value as the 
reference date for the expiration. 
The software I developed automatically launches such 
operationalisations. Therefore, the user has only to link the records from 
the table “person” with the names of the subsidiaries owned by the 
company under investigation and the following processes were 
automatically executed by the application. A second activity that users 
have to perform regards the definition of the partner typology. Indeed, 
a list of partners disclosed in patent applications under investigation is 
proposed to the user, who has to define if the partner is an industrial or a 
scientific entity. For the patents filed by Zeltia, two documents disclose a 
joint development with third parties. More specifically, the partners are: 
• DANA-FARBER CANCER INSTITUTE, INC., a scientific organization 
which conducts community-based programs in cancer 
prevention, detection, and control; 
• ORTHO BIOTECH PRODUCTS L.P., a biotech company (i.e. 
industrial entity) acquired by J&J in 2008. 
Considering that the number of investigated partners may be 
significant, I also developed the following function, which suggests the 
partner typology, but leaves the decision to the user. 
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function scientific_person($partner) { 
$partner=strtoupper($partner);  
if (  
strpos($partner,'COLLEGE') !== false || strpos($partner,'UNIVERSITY') !== false || 
strpos($partner,'UNIVERISTY') !== false || strpos($partner,'UNIVERSTY') !== false || 
strpos($partner,'MEDICAL CENTER') !== false || strpos($partner,'UNIVERSITAET') !== false 
|| strpos($partner,'UNIVERSITAT') !== false || strpos($partner,'CLINIC') !== false || 
strpos($partner,'INSTITUTE') !== false || strpos($partner,'INSTITUT') !== false || 
strpos($partner,'INSTYTUT') !== false || strpos($partner,'HOSPITAL') !== false || 
strpos($partner,'FOUNDATION') !== false || strpos($partner,'EDUCATION') !== false || 
(strpos($partner,'RESEARCH') !== false && strpos($partner,' INC') === false) || 
(strpos($partner,'RESEARCH') !== false && strpos($partner,' LTD') === false) || 
strpos($partner,'COUNCIL') !== false || 
(strpos($partner,'NATIONAL') !== false && strpos($partner,'INTERNATIONAL') === false) || 
(strpos($partner,'INST') !== false && strpos($partner,'SCIENCE') !== false) || 
(strpos($partner,'INST') !== false && strpos($partner,'TECH') !== false) || 
(strpos($partner,'INST') !== false && strpos($partner,'RES') !== false) || 
(strpos($partner,'INST') !== false && strpos($partner,'NAT') !== false) || 
strpos($partner,'INST OF') !== false || strpos($partner,'DEPARTMENT') !== false || 
strpos($partner,'MINISTER FOR') !== false || strpos($partner,'MINISTER OF') !== false ||  
strpos($partner,'MINISTRY OF') !== false || strpos($partner,'REGENTS') !== false || 
strpos($partner,'AGENCY') !== false || strpos($partner,'GOVERNMENT') !== false || 
strpos($partner,'GOVT') !== false || strpos($partner,'INTERUNIVERSITAIR') !== false || 
strpos($partner,'INTERUNIVERSITY') !== false || strpos($partner,'RECHERCHE') !== false || 
strpos($partner,'POLYTECHNIC') !== false || strpos($partner,'CENTRUM') !== false || 
strpos($partner,'CENTER FOR THE') !== false || strpos($partner,'UNIVERSITEIT') !== false || 
strpos($partner,'CONSORZIO PER LA RICERCA') !== false ||  strpos($partner,'ISTITUTO DI 
RICERCA') !== false || strpos($partner,'UNIVERSIT') !== false || strpos($partner,'ECOLE 
SUPERIEURE') !== false || strpos($partner,'CONSIGLIO NAZIONALE') !== false || 
strpos($partner,'COMMISSARIAT') !== false || strpos($partner,'POLITECNICO DI') !== false 
|| strpos($partner,'POLITECN') !== false || strpos($partner,'UNIVERSITE') !== false ||  
strpos($partner,'UNIVERSIDAD') !== false || strpos($partner,'ASSOCIATION') !== false || 
strpos($partner,'CONSEJO SUPERIOR') !== false || strpos($partner,'ASSOCIAZIONE') !== 
false || // strpos($partner,'UNITED STATES') !== false || da solo UNITED STATES non basta 
strpos($partner,'JUNAJTED STEHJTS') !== false || strpos($partner,'UNIV ') !== false || 
strpos($partner,' UNIV') !== false || (strpos($partner,'LABORATORY') !== false && 
strpos($partner,' INC') === false) || strpos($partner,'DEPT ') !== false || 
strpos($partner,'JUNIVERSITI') !== false || strpos($partner,'UNIVERSTIY') !== false ||  
strpos($partner,'ZENTRUM') !== false  || strpos($partner,'AUTHORITY') !== false  || 
strpos($partner,'THE STATE OF') !== false  || strpos($partner,'SCHOOL') !== false  || 
strpos($partner,'SENTRUM') !== false   
) 
 { $scientifi=1;}  
else { $ scientifi =0;} 
return $ scientifi;  
} 
 
(If at least one of these conditions is verified -i.e. the name contains at least one of these 
words – the partner is labelled as scientific, otherwise as industrial) 
 
After having completed this labelling, the user can run the script, 
which will display the results of the analysis for all the dimensions under 
investigation. Table 18 shows the values of CORE, NONCORE, EXPLOIT 
and EXPLOR within the 8 patents filed by Zeltia. Each variable exhibits the 
share of CPCs, which are labelled as core, non-core, exploitative or 
110 
 
explorative. For these operationalisations, I used CPCs until the main 
group, i.e. codes at level 4. 
Application number CORE NONCORE EXPLOIT EXPLOR 
EP20030779140 33.00% 67.00% 33.00% 67.00% 
EP20040714847 67.00% 33.00% 33.00% 67.00% 
EP20040720081 100.00% 0.00% 100.00% 0.00% 
EP20040768394 67.00% 33.00% 67.00% 33.00% 
EP20040798717 100.00% 0.00% 0.00% 100.00% 
EP20050075779 0.00% 100.00% 0.00% 100.00% 
EP20050077333 33.00% 67.00% 33.00% 67.00% 
EP20050803151 50.00% 50.00% 50.00% 50.00% 
Share 56.25% 43.75% 39.50% 60.50% 
Table 18. Focalization and technological strategies from Zeltia’s patents 
 For the focalization dimension, it is necessary to investigate the 
share of patent applications filed from t-1 to t-7 (i.e. the experience 
period) which contain each technological domain. 
For instance, for the application EP20030779140, with filing year 
2003, the following CPCs were extracted: 
• “A61K 38”, recorded in 17% of the patent applications between 
1996 and 2002, and then, considered as core, since it exceeds the 
10% threshold, as defined in section 3.3; 
• “C07K 7”, reported in 6% of filings from 1996 to 2002, labelled as 
non-core technological domain; 
• “C07K 14”, not disclosed in any patent application during the 
experience period, therefore considered as non-core. 
Since only one-third of the domains was labelled as core, CORE is 
33%, while NON-CORE is 67%. This means that the invention involves 2 
technological fields, which are not relevant for Zeltia, and only 1 on 
which the firm has focalized many R&D efforts in the experience period. 
The average focalization (i.e. CORE) detected from Zeltia’s patents is 
measured as the mean value from the 8 investigated patents and is 
equal to 56.25%. This means that Zeltia is strongly specialized in more than 
50% of technological domains recorded in its applications.  
Regarding the definition of technological strategies carried out by 
the firm, a CPC is labelled as exploitative if at least one patent containing 
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such CPC has been recorded in the previous years. As argued in section 
3.2, for the bio-pharmaceutical industry the period ranges from t-7 to t-4. 
Therefore, for the patent EP20030779140 filed in 2003 by Zeltia, the 
analysis is performed by considering patent applications from 1996 to 
1999. Among the three CPCs found in this patent, only “A61K 38” was 
labelled as exploitative, since 1 patent was filed from 1996 to 1999, while 
“C07K 7” and “C07K 14” are considered as explorative fields. Therefore, 
the invention has been developed by exploiting 1 technological field 
and exploring 2 new knowledge domains, thus EXPLOIT is 33% and 
EXPLOR 67%. Overall, from 2003 to 2005 Zeltia carries out prevalently an 
exploration strategy, since it covers the 60.5% of CPCs recorded in the 8 
patent documents. 
Regarding the dimension related to the “openness of the 
innovation process”, I employ the number of applicants collected for 
each patent. If the document records only Zeltia in the assignee field, 
the variable CLOSED is set to 1, otherwise 0. When partners are found 
within the field, I extract the partner typology: OPEN_SCI is equal to 1 if 
the partner is a scientific entity, otherwise OPEN_IND is set to 1. Table 19 
displays the results from Zeltia’s patent applications. The closed 
innovation strategy covers 75% of the total R&D efforts, while the two 
shares of open innovation strategies are both equal to 12.5%. 
Application number CLOSED OPEN_SCI OPEN_IND 
EP20030779140 1 0 0 
EP20040714847 1 0 0 
EP20040720081 0 1 0 
EP20040768394 1 0 0 
EP20040798717 1 0 0 
EP20050075779 1 0 0 
EP20050077333 1 0 0 
EP20050803151 0 0 1 
Share 75.00% 12.50% 12.50% 
Table 19. Openness of the innovation process from Zeltia’s patents 
As to the type of innovation dimension, I employ information 
provided by backward citations and “new combo” variables. Actually, 
following the operationalization described in section 3.5, I detect: 
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• an incremental innovation, where the patent discloses 
backward citations and the combination of CPCs was 
already used by prior art: 
• a modular innovation, if no citations to previous contributions 
were found and the variable “new combo” is equal to 0; 
• an architectural innovation, when the technology cites 
other patents and the combination is new; 
• a radical innovation, if no citations to prior art were 
uncovered and no patents using the same combination 
were found. 
Table 20 summarises the results obtained for Zeltia. Modular and 
radical innovations are more frequent, and each one covers 37.50% of 







INCR MOD ARCH RAD 
EP20030779140 0 1 0 0 0 1 
EP20040714847 0 0 0 1 0 0 
EP20040720081 0 0 0 1 0 0 
EP20040768394 0 0 0 1 0 0 
EP20040798717 0 1 0 0 0 1 
EP20050075779 1 0 1 0 0 0 
EP20050077333 3 1 0 0 1 0 
EP20050803151 0 1 0 0 0 1 
Share 12.50% 37.50% 12.50% 37.50% 
Table 20. Type of innovation from Zeltia’s patents 
Regarding the last dimension under investigation (i.e. quality of 
innovation output), three variables are used in order to define the impact 
of the technology: expiration date, forward citations and family size. 
Actually, if the patent is lapsed within the following 8 years from the 
application, the quality is automatically LOW. It is the case of 2 
applications filed by Zeltia (EP20050075779 and EP20050077333). For the 
other documents, it is necessary check market and technological 
impact, following the operationalization described in section 3.6. 
Actually, the patent is labelled as: 




• TECH, if only forward citations were recorded; 
• MARK, when only an increase of the family size was 
uncovered; 
• HIGH, if both forward citations and patent extensions were 
detected.  
Table 21 displays the result obtained for the 8 patent filed by Zeltia. 
The inventions are mainly featured by market quality, except for the two 









LOW TECH MARK HIGH 
EP20030779140 2099 0 25 0 0 1 0 
EP20040714847 2099 0 12 0 0 1 0 
EP20040720081 2099 0 7 0 0 1 0 
EP20040768394 2099 0 5 0 0 1 0 
EP20040798717 2099 0 1 0 0 1 0 
EP20050075779 2010 1 10 1 0 0 0 
EP20050077333 2007 0 23 1 0 0 0 
EP20050803151 2099 0 8 0 0 1 0 
Share 25.00% 0.00% 75.00% 0.00% 
Table 21. Quality of innovation output from Zeltia’s patents 
Therefore, the information collected for Zeltia can be used to 
perform a firm-level analysis, also to benchmark with competitors. 
Furthermore, by cumulating all the patent applications filed by a sample 
of firms it is possible to carry out an industry-level analysis. Indeed, in 
chapter 4 I present descriptive statistics regarding the whole sample 
under investigation, in which I have considered 23,000 patent 
application collected from PATSTAT. In addition, in section 4.7 two 
correlation analyses were performed in order to define the relationships 








segment CORE NONCORE EXPLOIT EXPLOR CLOSED OPEN_SCI OPEN_IND INCR MOD ARCH RAD LOW TECH MARK HIGH 
Abbott PH 5% 95% 77% 23% 100% 0% 0% 36% 12% 48% 3% 7% 1% 15% 77% 
Active BIO 0% 100% 0% 100% 100% 0% 0% 0% 50% 0% 50% 0% 0% 0% 100% 
Adtran TCE 17% 84% 0% 100% 100% 0% 0% 50% 0% 50% 0% 0% 0% 0% 100% 
Advanced Digital Broadcast SE 0% 100% 0% 100% 100% 0% 0% 33% 0% 67% 0% 0% 0% 67% 33% 
Advanced Micro Devices SE 42% 58% 88% 12% 96% 0% 4% 50% 7% 38% 5% 1% 1% 8% 90% 
Advanced Semiconductor Eng. SE 63% 37% 0% 100% 100% 0% 0% 0% 11% 67% 22% 0% 0% 11% 89% 
Advantest SE 65% 35% 72% 28% 100% 0% 0% 55% 2% 42% 2% 4% 0% 6% 91% 
Affymetrix BIO 48% 52% 73% 27% 100% 0% 0% 14% 43% 14% 29% 0% 0% 14% 86% 
Alexion BIO 59% 41% 0% 100% 100% 0% 0% 25% 25% 38% 13% 0% 0% 38% 63% 
Allergan PH 45% 55% 81% 19% 99% 1% 0% 36% 22% 28% 14% 1% 0% 13% 86% 
Almirall PH 24% 76% 82% 18% 100% 0% 0% 64% 36% 0% 0% 36% 0% 45% 18% 
Altera SE 53% 47% 54% 46% 100% 0% 0% 68% 0% 31% 1% 1% 0% 3% 96% 
Amgen BIO 44% 57% 75% 25% 92% 0% 8% 27% 11% 54% 8% 0% 0% 14% 86% 
Amkor Technology SE 100% 0% 100% 0% 100% 0% 0% 100% 0% 0% 0% 0% 0% 0% 100% 
Analog Devices SE 1% 99% 44% 56% 100% 0% 0% 50% 1% 49% 0% 0% 0% 4% 96% 
Apple CHOE 43% 57% 62% 38% 100% 0% 0% 43% 4% 50% 3% 0% 0% 2% 98% 
Applied Materials SE 52% 48% 86% 14% 100% 0% 0% 31% 12% 43% 14% 5% 0% 5% 90% 
ARM SE 45% 55% 26% 74% 92% 8% 0% 60% 6% 34% 0% 2% 2% 8% 88% 
Arris TCE 17% 83% 79% 21% 100% 0% 0% 26% 12% 47% 15% 2% 1% 4% 93% 
ASM International SE 56% 44% 71% 29% 96% 2% 2% 38% 6% 49% 8% 0% 0% 8% 92% 





segment CORE NONCORE EXPLOIT EXPLOR CLOSED OPEN_SCI OPEN_IND INCR MOD ARCH RAD LOW TECH MARK HIGH 
Asustek Computer CHOE 50% 50% 0% 100% 50% 9% 42% 50% 0% 0% 50% 0% 0% 0% 100% 
Atmel SE 32% 68% 43% 57% 100% 0% 0% 61% 2% 37% 0% 1% 0% 10% 89% 
ATMI SE 26% 74% 54% 46% 100% 0% 0% 41% 5% 53% 0% 2% 0% 2% 97% 
Austriamicrosystems SE 0% 100% 0% 100% 100% 0% 0% 60% 0% 40% 0% 80% 0% 0% 20% 
Avago Technologies SE 21% 79% 21% 79% 100% 0% 0% 50% 0% 50% 0% 2% 0% 8% 91% 
Avaya TCE 35% 65% 66% 34% 99% 0% 1% 31% 6% 57% 7% 0% 0% 6% 94% 
Axis CHOE 0% 100% 0% 100% 100% 0% 0% 0% 0% 100% 0% 100% 0% 0% 0% 
Bavarian BIO 72% 29% 18% 82% 100% 0% 0% 25% 0% 13% 63% 38% 0% 50% 13% 
Biotest PH 67% 33% 0% 100% 100% 0% 0% 33% 33% 33% 0% 0% 0% 67% 33% 
Boehringer PH 35% 65% 79% 21% 99% 1% 0% 24% 43% 23% 10% 20% 0% 45% 34% 
BristolMyers PH 18% 82% 79% 21% 97% 2% 1% 51% 10% 31% 8% 10% 3% 19% 68% 
Broadcom SE 8% 92% 82% 18% 100% 0% 0% 34% 2% 60% 3% 0% 0% 5% 94% 
Brocade Communications S. TCE 0% 100% 0% 100% 50% 0% 50% 50% 0% 50% 0% 0% 0% 0% 100% 
Brother Industries CHOE 22% 78% 22% 78% 67% 0% 33% 89% 0% 11% 0% 22% 11% 22% 44% 
BTG BIO 14% 86% 7% 93% 100% 0% 0% 13% 13% 13% 63% 50% 0% 13% 38% 
Bull CHOE 67% 33% 100% 0% 100% 0% 0% 100% 0% 0% 0% 0% 0% 67% 33% 
Cabot Microelectronics SE 75% 25% 73% 27% 100% 0% 0% 55% 16% 24% 5% 0% 0% 7% 93% 
Cadila Healthcare PH 16% 84% 0% 100% 100% 0% 0% 0% 33% 0% 67% 100% 0% 0% 0% 
Calix TCE 0% 100% 0% 100% 100% 0% 0% 50% 0% 50% 0% 0% 0% 0% 100% 
Canon CHOE 56% 44% 66% 34% 81% 6% 14% 61% 3% 33% 3% 3% 0% 6% 92% 
Celgene BIO 64% 36% 55% 45% 100% 0% 0% 37% 3% 50% 10% 7% 3% 13% 77% 
Chiesi PH 63% 38% 60% 40% 100% 0% 0% 25% 50% 8% 17% 33% 0% 42% 25% 
CHR PH 4% 96% 2% 98% 100% 0% 0% 50% 0% 25% 25% 25% 0% 25% 50% 





segment CORE NONCORE EXPLOIT EXPLOR CLOSED OPEN_SCI OPEN_IND INCR MOD ARCH RAD LOW TECH MARK HIGH 
Cisco Systems TCE 46% 54% 56% 44% 100% 0% 0% 36% 2% 58% 4% 1% 0% 3% 96% 
Comverse Technology TCE 50% 50% 40% 60% 100% 0% 0% 20% 40% 40% 0% 0% 0% 20% 80% 
Corning TCE 32% 68% 75% 25% 100% 0% 0% 39% 0% 61% 0% 1% 1% 4% 94% 
Cray CHOE 31% 69% 11% 89% 100% 0% 0% 53% 0% 47% 0% 0% 0% 6% 94% 
Cree SE 63% 37% 76% 24% 100% 0% 0% 43% 3% 53% 1% 0% 1% 1% 98% 
CSL BIO 0% 100% 0% 100% 0% 100% 0% 100% 0% 0% 0% 0% 0% 0% 100% 
CSR UK TCE 0% 100% 0% 100% 100% 0% 0% 50% 0% 50% 0% 0% 0% 25% 75% 
Cypress Semiconductor SE 9% 91% 16% 84% 100% 0% 0% 62% 0% 38% 0% 0% 3% 11% 86% 
Dell CHOE 15% 85% 8% 92% 100% 0% 0% 52% 15% 27% 6% 0% 0% 4% 96% 
Delta Electronics CHOE 67% 33% 65% 35% 100% 0% 0% 67% 11% 22% 0% 6% 0% 6% 89% 
Dendreon BIO 100% 0% 0% 100% 50% 0% 50% 50% 50% 0% 0% 0% 0% 50% 50% 
Dialog Semiconductor SE 5% 95% 18% 82% 100% 0% 0% 75% 3% 21% 0% 12% 0% 38% 49% 
Diamyd PH 0% 100% 0% 100% 100% 0% 0% 0% 33% 0% 67% 0% 0% 33% 67% 
Diebold CHOE 50% 50% 0% 100% 100% 0% 0% 40% 0% 60% 0% 0% 0% 0% 100% 
Dong-A Pharmaceutical PH 0% 100% 0% 100% 100% 0% 0% 0% 0% 100% 0% 0% 0% 0% 100% 
Dynavax Technologies BIO 100% 0% 33% 67% 100% 0% 0% 0% 33% 67% 0% 100% 0% 0% 0% 
Egis PH 36% 64% 0% 100% 100% 0% 0% 0% 100% 0% 0% 100% 0% 0% 0% 
Eisai PH 69% 31% 62% 39% 100% 0% 0% 13% 75% 6% 6% 6% 0% 44% 50% 
Elan PH 66% 34% 75% 25% 54% 31% 15% 23% 8% 38% 31% 8% 8% 8% 77% 
Electronics for imaging CHOE 50% 50% 57% 43% 100% 0% 0% 57% 4% 35% 4% 0% 0% 4% 96% 
EliLilly PH 19% 81% 70% 30% 95% 0% 5% 12% 37% 12% 38% 49% 2% 35% 14% 
ELMOS Semiconductor SE 43% 57% 20% 80% 67% 0% 33% 33% 0% 67% 0% 67% 0% 33% 0% 
EMC CHOE 67% 33% 83% 17% 100% 0% 0% 37% 10% 49% 4% 1% 3% 1% 95% 





segment CORE NONCORE EXPLOIT EXPLOR CLOSED OPEN_SCI OPEN_IND INCR MOD ARCH RAD LOW TECH MARK HIGH 
Entegris SE 34% 66% 36% 64% 97% 0% 3% 45% 0% 55% 0% 0% 0% 5% 95% 
Ericsson TCE 11% 89% 96% 4% 99% 0% 1% 40% 4% 48% 8% 14% 14% 7% 65% 
Evotec PH 23% 77% 28% 72% 60% 0% 40% 50% 0% 50% 0% 20% 0% 20% 60% 
Exelixis PH 8% 92% 8% 92% 100% 0% 0% 33% 0% 50% 17% 50% 0% 17% 33% 
Extreme Networks TCE 36% 64% 7% 93% 100% 0% 0% 42% 0% 58% 0% 0% 0% 0% 100% 
F5 Networks TCE 11% 89% 0% 100% 100% 0% 0% 67% 0% 33% 0% 0% 0% 0% 100% 
Fairchild Semiconductor SE 56% 44% 62% 38% 100% 0% 0% 43% 0% 57% 0% 0% 0% 4% 96% 
FEI SE 63% 38% 48% 52% 95% 0% 5% 14% 0% 81% 5% 5% 0% 0% 95% 
Finisar TCE 61% 39% 66% 34% 100% 0% 0% 53% 5% 41% 1% 0% 0% 6% 94% 
Forest PH 0% 100% 0% 100% 100% 0% 0% 100% 0% 0% 0% 0% 0% 0% 100% 
GedeonRichter PH 29% 71% 29% 71% 100% 0% 0% 0% 88% 0% 13% 75% 0% 25% 0% 
Gilead BIO 58% 42% 53% 47% 86% 9% 5% 10% 24% 41% 24% 7% 0% 52% 41% 
Glenmark Pharmaceuticals PH 0% 100% 0% 100% 100% 0% 0% 0% 100% 0% 0% 100% 0% 0% 0% 
GN Store Nord TCE 28% 72% 50% 50% 100% 0% 0% 33% 0% 50% 17% 0% 0% 17% 83% 
Hanmi Pharm PH 0% 100% 0% 100% 100% 0% 0% 100% 0% 0% 0% 100% 0% 0% 0% 
Harmonic TCE 0% 100% 0% 100% 100% 0% 0% 33% 33% 33% 0% 0% 0% 0% 100% 
Harris TCE 5% 95% 48% 52% 100% 0% 0% 35% 7% 54% 4% 0% 0% 8% 92% 
Hewlett-Packard CHOE 3% 97% 84% 16% 100% 0% 0% 55% 2% 43% 1% 1% 1% 11% 87% 
Hikma PH 0% 100% 0% 100% 100% 0% 0% 100% 0% 0% 0% 0% 0% 100% 0% 
Hisamitsu Pharmaceutical PH 0% 100% 0% 100% 100% 0% 0% 100% 0% 0% 0% 0% 0% 0% 100% 
HTC TCE 34% 66% 9% 91% 100% 0% 0% 21% 7% 64% 7% 57% 14% 14% 14% 
Huawei Technologies TCE 0% 100% 0% 100% 100% 0% 0% 0% 0% 100% 0% 50% 0% 0% 50% 
Hynix Semiconductor SE 25% 75% 0% 100% 0% 0% 100% 65% 0% 35% 0% 75% 0% 15% 10% 





segment CORE NONCORE EXPLOIT EXPLOR CLOSED OPEN_SCI OPEN_IND INCR MOD ARCH RAD LOW TECH MARK HIGH 
Integrated Device Technology SE 17% 83% 7% 93% 100% 0% 0% 38% 28% 24% 10% 0% 0% 10% 90% 
Intel SE 0% 100% 85% 15% 100% 0% 0% 45% 3% 49% 4% 0% 0% 5% 95% 
Interdigital SE 41% 59% 70% 30% 100% 0% 0% 24% 9% 53% 14% 0% 0% 6% 93% 
Intermec CHOE 40% 60% 10% 90% 100% 0% 0% 60% 10% 20% 10% 0% 0% 0% 100% 
International Rectifier SE 42% 58% 52% 48% 100% 0% 0% 45% 1% 52% 2% 1% 3% 8% 88% 
Intersil SE 34% 66% 24% 76% 100% 0% 0% 59% 7% 34% 0% 0% 0% 3% 97% 
Ipsen PH 0% 100% 0% 100% 100% 0% 0% 0% 100% 0% 0% 100% 0% 0% 0% 
Isis BIO 83% 17% 93% 7% 96% 4% 0% 37% 7% 48% 7% 4% 0% 19% 78% 
J&J PH 36% 64% 87% 13% 99% 0% 1% 30% 7% 56% 7% 7% 1% 9% 83% 
JDS Uniphase TCE 19% 81% 40% 60% 100% 0% 0% 34% 2% 63% 2% 0% 0% 10% 90% 
Juniper Networks TCE 63% 37% 63% 37% 100% 0% 0% 54% 0% 46% 0% 0% 0% 0% 100% 
Kla-Tencor SE 55% 45% 74% 26% 100% 0% 0% 45% 1% 54% 0% 0% 1% 6% 93% 
Krka PH 49% 51% 0% 100% 100% 0% 0% 48% 28% 24% 0% 38% 0% 21% 41% 
Kulicke & Soffa SE 65% 35% 63% 37% 100% 0% 0% 8% 8% 83% 0% 0% 0% 8% 92% 
Lam Research SE 61% 39% 77% 23% 100% 0% 0% 42% 4% 47% 6% 0% 0% 5% 95% 
Lattice Semiconductor SE 33% 67% 15% 85% 100% 0% 0% 59% 0% 38% 3% 0% 0% 8% 92% 
Lenovo CHOE 25% 75% 22% 78% 100% 0% 0% 48% 0% 52% 0% 0% 0% 2% 98% 
Lexmark CHOE 52% 48% 81% 19% 100% 0% 0% 58% 4% 36% 2% 2% 2% 12% 83% 
Linear Technology SE 36% 64% 20% 80% 100% 0% 0% 62% 9% 25% 4% 2% 2% 2% 94% 
Logitech international CHOE 31% 69% 39% 61% 100% 0% 0% 29% 20% 40% 11% 0% 0% 3% 97% 
LSI Corp SE 38% 62% 44% 56% 95% 0% 5% 43% 10% 43% 5% 0% 0% 5% 95% 
Lundbeck PH 34% 66% 47% 53% 89% 7% 4% 22% 48% 11% 19% 41% 0% 41% 19% 
Lupin PH 33% 67% 0% 100% 100% 0% 0% 33% 0% 33% 33% 33% 0% 0% 67% 





segment CORE NONCORE EXPLOIT EXPLOR CLOSED OPEN_SCI OPEN_IND INCR MOD ARCH RAD LOW TECH MARK HIGH 
Marvell Technology SE 28% 72% 0% 100% 100% 0% 0% 50% 0% 46% 4% 0% 0% 13% 88% 
Maxim Integrated Products SE 21% 79% 17% 83% 100% 0% 0% 33% 0% 67% 0% 0% 0% 17% 83% 
MediaTek SE 21% 79% 38% 62% 99% 1% 0% 47% 14% 29% 11% 1% 0% 11% 89% 
MediGene BIO 0% 100% 0% 100% 100% 0% 0% 50% 25% 25% 0% 25% 0% 25% 50% 
Medivir PH 9% 92% 9% 92% 100% 0% 0% 50% 0% 0% 50% 0% 0% 100% 0% 
MEMC Electronics Materials SE 52% 48% 27% 73% 100% 0% 0% 41% 18% 35% 6% 0% 0% 0% 100% 
MerckDE PH 19% 81% 57% 43% 96% 0% 4% 22% 31% 28% 19% 33% 0% 43% 24% 
MerckUS PH 21% 79% 66% 34% 89% 5% 6% 15% 35% 21% 29% 40% 1% 9% 50% 
Mercury Computer Systems SE 0% 100% 0% 100% 100% 0% 0% 0% 0% 100% 0% 0% 0% 0% 100% 
Merz PH 53% 47% 30% 70% 100% 0% 0% 40% 40% 0% 20% 60% 20% 20% 0% 
Micrel SE 12% 88% 12% 88% 100% 0% 0% 65% 6% 29% 0% 0% 6% 6% 88% 
Microchip Technology SE 12% 88% 13% 87% 100% 0% 0% 50% 26% 13% 11% 3% 0% 8% 89% 
Micron Technology SE 44% 56% 80% 20% 100% 0% 0% 41% 2% 53% 3% 0% 0% 4% 96% 
Micronic Mydata SE 76% 24% 75% 25% 93% 0% 7% 50% 0% 43% 7% 7% 0% 7% 86% 
Microsemi SE 54% 46% 0% 100% 100% 0% 0% 67% 0% 33% 0% 0% 0% 0% 100% 
Mitel Networks TCE 0% 100% 0% 100% 100% 0% 0% 43% 0% 57% 0% 0% 0% 29% 71% 
MKS Instruments SE 24% 76% 43% 57% 100% 0% 0% 56% 4% 38% 2% 0% 0% 6% 94% 
Morphosys BIO 75% 25% 75% 25% 0% 0% 100% 0% 0% 100% 0% 0% 100% 0% 0% 
Motorola TCE 1% 99% 88% 12% 99% 0% 1% 42% 6% 45% 7% 2% 0% 7% 92% 
Mylan PH 73% 27% 70% 30% 100% 0% 0% 40% 20% 0% 40% 0% 0% 20% 80% 
NCR CHOE 30% 70% 42% 58% 100% 0% 0% 26% 23% 32% 19% 0% 0% 6% 94% 
Nektar BIO 15% 85% 4% 96% 100% 0% 0% 0% 0% 33% 67% 33% 0% 0% 67% 
Neopost CHOE 39% 61% 27% 73% 100% 0% 0% 28% 0% 61% 11% 0% 0% 17% 83% 





segment CORE NONCORE EXPLOIT EXPLOR CLOSED OPEN_SCI OPEN_IND INCR MOD ARCH RAD LOW TECH MARK HIGH 
NeuroSearch BIO 78% 22% 78% 22% 100% 0% 0% 0% 67% 0% 33% 100% 0% 0% 0% 
NicOx PH 24% 76% 53% 47% 100% 0% 0% 14% 43% 14% 29% 71% 0% 14% 14% 
Nokia TCE 12% 88% 90% 10% 100% 0% 0% 25% 13% 42% 19% 1% 1% 4% 94% 
Novartis PH 20% 80% 77% 23% 90% 3% 7% 20% 37% 16% 28% 47% 2% 36% 16% 
NovoNordisk PH 40% 60% 80% 20% 95% 0% 5% 27% 9% 59% 5% 0% 0% 23% 77% 
NPS BIO 81% 19% 0% 100% 33% 0% 67% 33% 33% 33% 0% 33% 0% 0% 67% 
NVIDIA SE 18% 82% 35% 65% 100% 0% 0% 50% 1% 44% 5% 0% 0% 4% 96% 
OKI Electric TCE 0% 100% 0% 100% 100% 0% 0% 100% 0% 0% 0% 0% 0% 0% 100% 
OmniVision Technologies SE 66% 34% 68% 32% 100% 0% 0% 50% 12% 24% 14% 0% 0% 14% 86% 
ON Semiconductor SE 53% 47% 33% 67% 99% 0% 1% 48% 2% 47% 3% 0% 2% 19% 80% 
Onyx PH 5% 95% 5% 95% 100% 0% 0% 0% 33% 33% 33% 0% 0% 33% 67% 
Orexo PH 0% 100% 0% 100% 100% 0% 0% 0% 0% 0% 100% 100% 0% 0% 0% 
Otsuka PH 50% 50% 48% 52% 95% 5% 0% 21% 42% 5% 32% 37% 0% 32% 32% 
PACE TCE 33% 67% 33% 67% 100% 0% 0% 0% 0% 100% 0% 100% 0% 0% 0% 
Pantech TCE 0% 100% 0% 100% 100% 0% 0% 0% 100% 0% 0% 0% 0% 100% 0% 
Perrigo PH 17% 83% 17% 83% 100% 0% 0% 100% 0% 0% 0% 17% 0% 33% 50% 
Pfizer PH 31% 69% 80% 20% 97% 1% 2% 23% 34% 19% 25% 49% 0% 12% 39% 
Pitney Bowes CHOE 38% 62% 70% 30% 99% 0% 1% 32% 11% 40% 18% 0% 0% 13% 87% 
Plantronics TCE 49% 51% 23% 77% 100% 0% 0% 15% 8% 38% 38% 0% 0% 0% 100% 
PMC-Sierra SE 0% 100% 0% 100% 100% 0% 0% 100% 0% 0% 0% 0% 0% 0% 100% 
Polycom TCE 60% 40% 48% 52% 100% 0% 0% 31% 0% 54% 15% 0% 0% 0% 100% 
Powerwave Technologies TCE 74% 26% 25% 75% 100% 0% 0% 45% 0% 55% 0% 0% 0% 0% 100% 
Qiagen BIO 63% 37% 77% 23% 89% 11% 0% 67% 0% 28% 6% 17% 0% 22% 61% 





segment CORE NONCORE EXPLOIT EXPLOR CLOSED OPEN_SCI OPEN_IND INCR MOD ARCH RAD LOW TECH MARK HIGH 
Qualcomm TCE 20% 80% 83% 17% 100% 0% 0% 41% 2% 56% 2% 0% 0% 3% 96% 
Quantum CHOE 61% 39% 80% 20% 100% 0% 0% 49% 8% 36% 7% 0% 0% 13% 87% 
Radiall TCE 0% 100% 0% 100% 100% 0% 0% 0% 100% 0% 0% 0% 0% 0% 100% 
Rambus SE 49% 51% 52% 48% 99% 1% 0% 49% 4% 47% 0% 0% 0% 4% 96% 
Regeneron BIO 83% 17% 83% 17% 100% 0% 0% 43% 29% 14% 14% 14% 0% 57% 29% 
Research in motion TCE 30% 70% 52% 48% 100% 0% 0% 49% 2% 47% 2% 64% 0% 9% 26% 
RF Micro Devices SE 32% 68% 13% 87% 89% 0% 11% 11% 0% 78% 11% 0% 0% 0% 100% 
Ricoh CHOE 50% 50% 69% 31% 99% 0% 1% 49% 0% 50% 1% 3% 0% 2% 95% 
Roche PH 14% 86% 82% 18% 97% 2% 1% 41% 14% 38% 8% 35% 0% 21% 44% 
Rohm SE 23% 77% 8% 92% 100% 0% 0% 62% 5% 32% 2% 3% 0% 6% 91% 
SanDisk SE 49% 51% 83% 17% 98% 0% 2% 40% 0% 59% 1% 0% 0% 0% 100% 
Seagate Technology CHOE 47% 53% 63% 37% 100% 0% 0% 55% 5% 33% 6% 4% 10% 5% 82% 
Seiko Epson CHOE 9% 91% 39% 61% 93% 1% 6% 57% 2% 39% 1% 9% 1% 13% 76% 
Shire PH 60% 40% 52% 48% 100% 0% 0% 50% 20% 30% 0% 10% 0% 50% 40% 
Sierra Wireless TCE 28% 72% 19% 81% 100% 0% 0% 31% 38% 15% 15% 0% 0% 8% 92% 
Silence BIO 50% 50% 0% 100% 100% 0% 0% 0% 100% 0% 0% 0% 0% 0% 100% 
Silicon Graphics International CHOE 50% 50% 0% 100% 100% 0% 0% 50% 25% 25% 0% 0% 0% 0% 100% 
Silicon Image SE 39% 61% 20% 80% 89% 0% 11% 56% 11% 33% 0% 11% 11% 0% 78% 
Silicon Laboratories SE 21% 79% 20% 80% 100% 0% 0% 49% 2% 47% 2% 0% 0% 2% 98% 
Smartrac SE 29% 71% 17% 83% 100% 0% 0% 0% 0% 100% 0% 0% 0% 0% 100% 
Soitec SE 69% 31% 15% 85% 86% 10% 3% 48% 3% 48% 0% 31% 3% 14% 52% 
Sonus Networks TCE 0% 100% 0% 100% 100% 0% 0% 50% 50% 0% 0% 0% 0% 0% 100% 
Spirent Communications TCE 23% 77% 0% 100% 100% 0% 0% 50% 0% 50% 0% 10% 0% 10% 80% 





segment CORE NONCORE EXPLOIT EXPLOR CLOSED OPEN_SCI OPEN_IND INCR MOD ARCH RAD LOW TECH MARK HIGH 
Stats ChipPAC SE 67% 33% 0% 100% 100% 0% 0% 0% 13% 80% 7% 0% 0% 7% 93% 
STMicroelectronics SE 0% 100% 73% 27% 91% 1% 8% 50% 2% 45% 3% 35% 0% 26% 38% 
Sun Pharmaceutical Industries PH 0% 100% 0% 100% 67% 0% 33% 33% 0% 33% 33% 33% 0% 33% 33% 
Suss MicroTec SE 0% 100% 0% 100% 100% 0% 0% 100% 0% 0% 0% 0% 0% 0% 100% 
Synaptics CHOE 72% 28% 66% 34% 100% 0% 0% 63% 0% 25% 13% 0% 0% 0% 100% 
Taisho Pharmaceutical PH 75% 25% 25% 75% 100% 0% 0% 50% 50% 0% 0% 0% 0% 50% 50% 
Takeda Pharmaceutical PH 16% 84% 4% 96% 100% 0% 0% 44% 22% 11% 22% 22% 11% 44% 22% 
Telit Communications TCE 0% 100% 0% 100% 100% 0% 0% 0% 0% 100% 0% 0% 100% 0% 0% 
Tellabs TCE 41% 59% 65% 35% 100% 0% 0% 50% 24% 15% 12% 6% 0% 15% 79% 
Teradyne SE 52% 48% 65% 35% 100% 0% 0% 63% 2% 34% 2% 2% 0% 9% 89% 
Tessera Technologies SE 60% 40% 40% 60% 100% 0% 0% 5% 5% 86% 5% 0% 0% 5% 95% 
Teva PH 44% 56% 44% 56% 95% 0% 5% 34% 20% 46% 0% 22% 2% 10% 66% 
Texas Instruments SE 10% 90% 75% 25% 99% 0% 1% 43% 6% 44% 7% 0% 0% 15% 84% 
Theravance PH 66% 34% 42% 58% 100% 0% 0% 0% 38% 13% 50% 25% 0% 63% 13% 
ThromboGenics BIO 0% 100% 0% 100% 100% 0% 0% 100% 0% 0% 0% 0% 0% 100% 0% 
Transgene BIO 40% 60% 60% 40% 0% 100% 0% 0% 100% 0% 0% 0% 0% 100% 0% 
Triquint Semiconductor SE 21% 79% 21% 79% 100% 0% 0% 13% 7% 60% 20% 0% 0% 13% 87% 
UCB PH 61% 39% 26% 74% 100% 0% 0% 17% 17% 33% 33% 17% 0% 50% 33% 
United BIO 0% 100% 0% 100% 100% 0% 0% 50% 0% 50% 0% 0% 0% 0% 100% 
Valeant PH 0% 100% 0% 100% 100% 0% 0% 33% 0% 67% 0% 0% 0% 33% 67% 
VeriFone Systems CHOE 0% 100% 0% 100% 100% 0% 0% 50% 0% 50% 0% 0% 0% 50% 50% 
Vertex BIO 84% 16% 69% 31% 100% 0% 0% 32% 20% 28% 20% 40% 12% 4% 44% 
Viasat TCE 31% 70% 14% 86% 100% 0% 0% 17% 0% 83% 0% 0% 0% 0% 100% 
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VTech TCE 36% 64% 6% 94% 100% 0% 0% 38% 0% 62% 0% 0% 0% 9% 91% 
WarnerChilcott PH 61% 39% 0% 100% 100% 0% 0% 33% 0% 0% 67% 0% 0% 33% 67% 
Watson PH 92% 8% 46% 54% 100% 0% 0% 0% 25% 50% 25% 0% 0% 25% 75% 
Western Digital CHOE 5% 95% 5% 95% 100% 0% 0% 57% 0% 43% 0% 0% 0% 14% 86% 
Wolfson Microelectronics SE 0% 100% 0% 100% 100% 0% 0% 100% 0% 0% 0% 0% 0% 0% 100% 
Xerox CHOE 31% 69% 84% 16% 100% 0% 0% 46% 7% 40% 6% 0% 0% 8% 92% 
Xilinx SE 33% 67% 72% 28% 100% 0% 0% 42% 0% 58% 0% 0% 0% 0% 100% 
Xyratex CHOE 0% 100% 0% 100% 100% 0% 0% 100% 0% 0% 0% 100% 0% 0% 0% 
Zeltia PH 56% 44% 40% 61% 75% 13% 13% 13% 38% 13% 38% 25% 0% 75% 0% 
ZyXEL Communications TCE 29% 71% 0% 100% 100% 0% 0% 29% 14% 43% 14% 86% 0% 0% 14% 
 
 
